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ABSTRACT 
 
Sonic hedgehog (Shh) signaling regulates critical processes during embryonic development and 
in homeostasis of adult tissues. Deregulated pathway activity is a major factor underlying the 
etiology of numerous developmental disorders and cancers. In this dissertation, I investigated 
early neonatal cerebellar development, where I identified that the Purkinje neuron utilizes bi-
directional distribution of Shh to centrally regulate neurogenesis, and to expand a previously 
unappreciated stem cell – progenitor cell lineage in the white matter niche. Additionally, I 
established a novel mouse model for a soft tissue sarcoma, Ewing’s sarcoma. These findings 
provide new understanding of how the Purkinje neuron oversees cerebellar development, as well 
as key insight into the molecular underpinnings of a Shh-driven sarcoma variant.  
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 CHAPTER I
 
 
 
GENERAL INTRODUCTION 
 
 
 
During embryonic development the rudiments of the central nervous system (CNS) emerge as 
the neural tube is progressively partitioned along the anterior-posterior axis. Ontogeny of the 
cerebellum, or “mini-brain” as it is also known, initiates from rhombomere one at a region that 
is destined to become the hindbrain-midbrain boundary (Sotelo, 2004). The cerebellum is a brain 
structure that is well-known for it’s absolute requirement in coordinating fine motor control, but 
in recent years a contribution to mediating higher cognitive functions has been revealed 
concomitant with the identification of important neuronal connections between the cerebellum 
and the pre-frontal cortex (White and Sillitoe, 2012).  
 
Historically, the cerebellum has provided a “go-to” system for pioneering neurobiologists, 
facilitating several of the most fundamental concepts in neuroscience. The architecture of the 
cerebellar cortex naturally lends itself to the study of complex neurodevelopmental processes. It 
displays a stereotypical laminar structure in which only a limited number of well-characterized 
neuronal subtypes are encountered, and they are divided into two major categories based on 
neurotransmitter profile: GABAergic or Glutamatergic. The mature cerebellum contains four 
cortical layers, the outer-most molecular layer (ML), which overlies the Purkinje cell layer 
(PCL). Beneath that is a hyper-dense layer called the internal granule cell layer (IGL), comprised 
almost entirely of granule cells, the most abundant neuronal type in the entire brain. At the 
cerebellar core is a layer of white matter (WM), which mostly contains myelinated axonal 
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projections and glial cell types, oligodendrocytes and astrocytes (Sillitoe and Joyner, 2007; 
Sotelo, 2004). 
 
Outside-to-inside, cerebellar neurons include the inhibitory, GABA-expressing component: 
basket and stellate cells (ML), Purkinje neurons (PCL), Golgi and Lugaro cells (IGL), and a 
subset of deep cerebellar nuclei (DCN) neurons within the core of the WM. The cerebellar 
excitatory, Glutamate-expressing component includes candelabrum cells (PCL), granule cells 
and unipolar brush cells (IGL), and the remaining DCN neurons (WM). All of these neurons are 
arranged into a complicated circuit the central node of which is the Purkinje neuron (PN). PNs 
not only received input from this cerebellar circuit, but also exchange input with clusters of 
neurons housed within the brain stem and spinal cord, making them the only projection neurons 
within the cerebellar system, and all others local circuit interneurons. Collectively, that totals 
only nine neuronal cell types, for which the morphology and localization is known. One last cell 
type of note are the Bergmann glial cells, a population of unipolar astrocytes occupying the PCL 
that appear to play an important role in the development and maintenance of the cerebellar 
system (Sillitoe and Joyner, 2007; Sotelo, 2004). 
  
 
This description accounts for the basic outline of cerebellar cortical architecture, or what the 
cerebellum looks like as a finished product of normal development.  However, much is also 
known regarding the origin of the cell types described above, and of the foliation events that 
impart the cerebellum with a distinctively folded cortex, a striking structural motif not seen 
elsewhere in the CNS. The origin of all nine neuronal subtypes can be traced back to two 
neuroepithelial layers of the embryonic cerebellar anlagen, a nascent but cylindrical structure, 
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and are born in an “inside-out” sequence with the inner-most cells appearing first (Leto et al., 
2009). The ventricular zone (VZ), which is adjacent to the hindbrain 4th ventricle, harbors 
neuronal stem and progenitor cells with potential to eventually furnish all GABAergic neurons 
and glia (Altman J, 1997). Progenitor cells delaminate form the VZ, migrate radially into the 
cerebellar primordium and either become the first born GABAergic neurons or persist 
postnatally as progenitors within the presumptive white matter (PWM) that eventually give rise 
to the largest fraction of the inhibitory component, basket and stellate cells (Leto et al., 2010). 
 
Meanwhile, progenitors in the adjacent rhombic lip (RL) give rise exclusively to the 
Glutamatergic component. Granule cell precursors (GCPs) exit the RL and undergo tangential 
migration to form the external granule cell layer (EGL), a transient germinal layer that envelops 
the growing cerebellum until postnatal day 15 in mice. Intense clonal expansion of GCPs is the 
driving force behind cerebellar growth and foliation. As they exit the cell cycle, GCPs then 
migrate inward, forming the IGL, and as developmental time progresses the EGL disappears, 
leaving the ML exposed at the superficial, pial surface of the cerebellum (Machold R., 2005). 
 
 
Additionally, much is also known about the regulation of cerebellar development, in particular 
the transcriptional code necessary for segregating the two major neuronal lineages. Expression of 
the transcription factor Atoh1 is needed to specify the Glutamatergic lineage, while Ptf1a 
function is required to induce GABAergic fate (Hoshino et al., 2005; Machold R., 2005). The 
molecular signals responsible for expanding these lineages and dictating subtype choice are not 
at all that well understood, but it is clear that a secreted signaling molecule, called Sonic 
hedgehog (Shh), is the principal factor that induces cellular proliferation of GCPs, and is thus 
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required for cerebellar growth (Dahmane and Ruiz i Altaba, 1999; Lewis P.M., 2004; Wallace, 
1999; Wechsler-Reya and Scott, 1999).  
 
Shh is a lipid-modified protein from a family of three mammalian hedgehog (Hh) isoforms 
(Ingham PW, 2001). Originally, the Hh gene was discovered in a genetic mutational screen in the 
fruit fly, Drosophila melanogaster, in which mutant embryos failed to undergo correct segment 
patterning and ultimately were small, roundish-looking and covered in bristles, similar to a 
hedgehog. Findings from this screen led to the eventual Nobel prize in physiology or medicine in 
1995 for Eric Wieschaus and Christiane Nusslein-Volhard, who along with other investigators 
uncovered the genes encoding the core components of the Hh signaling cascade. In flies, Hh 
protein is secreted by producing cells and is transmitted over some distance to receiving cells 
where it binds to a 12-pass transmembrane receptor, Patched1 (Ptch1). This binding event 
between Hh and Ptch1 relieves inhibition on a second transmembrane protein, Smoothened 
(Smo), allowing it to potentiate an intracellular cascade culminating in activation of target gene 
expression, which is mediated by the transcription factor, Cubitus interruptus (Ci). In the absence 
of Hh, Ci is maintained as a transcriptional repressor of target genes (Ingham PW, 2001).  
 
Though very similar in terms of basic outline, the pathway in mammals is somewhat more 
complex. However, the core components remain the same; Hh binds to Ptch1, relieving 
inhibition of Smo. The transcriptional repressor/ activator functions of Ci are carried out by a 
family of three proteins, the Glioma-associated (Gli1) transcription factors, Gli1, Gli2 and Gli3. 
Gli1 and 2 primarily mediate activation, while in the absence of Hh ligand repression is mediated 
by Gli3. Another significant difference between invertebrate and vertebrate Hh signaling is that 
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the latter requires a specialized microtubule-based cellular organelle called a primary cilium 
(Huangfu and Anderson, 2005). All mammalian cells project a single primary cilium that serves 
as a cellular antenna, enabling cells to perceive cues within their local environment. Core Hh 
components localize to the cilium, and ciliary function is absolutely required for transducing 
pathway activity intracellularly (Haycraft C et al., 2005). However, invertebrate Hh signaling 
does not require this cellular structure.  
 
A number of Hh target genes have been identified, the products of which act as downstream 
effectors of Hh signaling to mediate diverse and context-dependent processes. Two core pathway 
components, Ptch1 and Gli1, are both Shh target genes themselves, providing reliable read-outs 
to identify Shh-responding cells. Classically, Hh signaling is known to mediate two major 
functions, it is known to act as either a morphogen or a mitogen, meaning it induces cellular fate 
choices or cellular division, respectively (Fuccillo et al., 2006). Just prior to mid-embryogenesis 
in the ventral neural tube, or floor plate, where notochord-derived Shh is known to act (and later 
floor plate-derived Shh), specific neural cells fates are determined via induction of target gene 
expression (Chiang et al., 1996). One example is the transcription factor Nkx2.2, which 
designates the progenitor domain of V3 interneurons (Vokes et al., 2007). Another classic 
example of Shh-mediated patterning is the developing limb bud where Shh expressed in the 
posterior compartment is required to establish digit identity. Genetic and chemical studies have 
shown that Shh signaling is absolutely required for patterning these regions, among others, and 
severe defects in axial patterning result in the absence of normal Shh signaling (Chiang et al., 
1996; Cooper et al., 1998).  
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As mentioned above, Shh also provides an instructive cue that induces cellular proliferation, and 
there are many examples during development and in the homeostasis of adult tissues where this 
function is of great importance. The clonal expansion of GCPs that transforms the cerebellum 
into an extensively foliated structure is driven by mitogenic Shh activity. Long after the EGL has 
vanished and the adult brain structure is completed, Shh continues to maintain proliferative 
progenitor populations in forebrain regions, in particular the subgranular zone (SGZ) in the 
hippocampal dentate gyrus, and the subventricular zone (SVZ) of the lateral ventricles (Fuccillo 
et al., 2006). In addition to this function, Shh also maintains quiescent stem cell populations 
residing in both germinal zones (Ahn and Joyner, 2005). Even outside the CNS, Shh maintains 
stem cell populations. In the hair follicle stem cell niche, Shh signals to basal progenitors within 
the bulge domain that maintain the structure throughout life (Brownell et al., 2011; Chiang et al., 
1999). An important and not well-understood issue is what cellular source provides Shh ligand to 
these critical regions, and indeed this is an area of active investigation. The study presented here 
in CHAPTER III will address this very idea, by describing a role for Purkinje neuron-derived
Shh in the PWM of the neonatal cerebellum (Fleming et al., 2013).  
 
 
Since Shh function is such an important player in maintaining proliferative populations and stem 
cells, it may not a great stretch of imagination to realize that deregulation of this potent 
mitogenic cue can also lead to oncogenic transformation. The big three cancer types associated 
with oncogenic Shh pathway activity are medulloblastoma (cerebellar cancer arising from 
GCPs), basal cell carcinoma (skin cancer arising from hair follicle stem cells) and 
rhabdomyosarcoma (soft tissue sarcoma linked to precursors of muscle and fat). Mutations 
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leading to these forms of cancer are most typically associated with deactivation of Ptch1, or 
activating mutations in Smo (Ruiz i Altaba et al., 2002). 
 
Rhabdomyosarcomas (RMS) fall within the category of small round cell sarcomas (SRCS), 
which is a broad spectrum of cancer entities (Kikuchi et al., 2011). Oncogenic Shh pathway 
activity has only been linked so far to RMS, however, the study described here in CHAPTER IV 
will present a strong argument that activation of human GLI2 leads to a different sarcoma 
variant, the Ewing’s family of tumors (EFT). One major difference that distinguishes RMS from 
EFT is line of differentiation, RMS are characterized and diagnosed based upon myogenic 
differentiation. These sarcomas typically express molecular markers of differentiated muscle 
cells (Desmin), or muscle precursors (MyoD, Myogenin, Myf5 and Pax7) (Lessnick et al., 2009). 
However, Ewing’s sarcoma, first described by James Ewing in 1975 have primarily received a 
diagnosis of exclusion since these sarcoma variants do not exhibit an obvious line of 
differentiation. Instead, members of the Ewing’s family, which include osteosarcoma, 
extraosseous sarcoma, and primitive neuroectodermal tumors (PNETs), receive diagnostic 
conformation based upon the presence of a specific reciprocal chromosomal translocation event, 
t(11, 22); (q24, q12) (Lessnick et al., 2009).   
 
This event fuses the trans activation domain of the TET protein, EWS, with the DNA-binding 
domain of ETS transcription factor, FLI1, producing a chimeric transcription factor, EWS-FLI1. 
This resulting oncoprotein is thought to be associated with >95% of EFT cases. Genomic studies 
have indicated that fusion redirects targeting of FLI1 to cancer associated genes, whereas it 
typically binds within proximal promoter elements of genes associated with development of the 
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hematopoietic system where it is known to play an important role (Liu et al., 2008; Patel et al., 
2012).  
 
EFT are highly aggressive sarcomas, most common in children and young adults, and require 
aggressive chemotherapy treatment programs. Although EWS-FLI1 appears to be an important 
mediator of EFT formation, the key molecules that act downstream of EWS-FLI1 are not known. 
No doubt the lack of this knowledge, along with a protracted absence of genetic mouse models 
for EFT has hindered the ability of researchers to develop new and more powerful diagnostic and 
treatment resources. Despite multiple attempts, no genetically-inducible mouse model currently 
exists for EFT, likely attributable to the lethality associated with introduction of EWS-FLI1 (Lin 
et al., 2008; Torchia et al., 2007). I will argue in CHAPTER IV that GLI2 is an important 
downstream effector of EWS-FLI1, and that GLI2 activation is sufficient to induce an EFT-like 
sarcoma phenotype in mice. 
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CHAPTER II
 
 
 
PROLOGUE 
 
 
 
In this section I will present the two areas of research in which I have been most engaged and 
from which the most significant findings have come. Although, on the surface, these research 
interests may seem somewhat disconnected, they are strongly linked by several important 
common themes. Among these connections is the hedgehog signaling pathway, particularly the 
Sonic hedgehog (Shh) signaling molecule that is absolutely required for many disparate 
processes during development and for homeostasis in adult tissues.  
 
The Shh signal is indeed potent, necessitating that a tight regulatory balance over pathway 
activity be in place to ensure that disorder does not ensue, as deregulated Shh signaling has been 
linked to the etiology of numerous developmental disorders and cancers. Though many players 
in the Shh pathway have been described, my work has revolved around core components: the 
receptor Patched1 (Ptch1), the signal transducer Smoothened (Smo), and the Gli transcriptional 
regulators. The respective functions of these factors are essential for mediating appropriate 
pathway activity, which can be a powerful oncogenic force when deregulated. For example, 
consider Gorlin’s syndrome, which is caused by an inherited loss of function mutation in 
PTCH1, resulting in basal cell carcinoma (skin cancer), medulloblastoma (CNS cancer) and 
Rhabdomyosarcoma (soft tissue cancer) (Ruiz i Altaba et al., 2002). 
 
In 2008 a “hot topic’ in the Shh research community was the role of the primary cilium in 
transmitting the Shh signal intracellularly. Previous to 2004 the primary cilium was a rather 
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overlooked cellular organelle, however its connection to the Shh pathway, and to polycystic 
kidney disease, helped potentiate renewed interest in the structure’s importance. When I entered 
the Chiang lab, a former student, Xi Huang, had just realized a possible contribution of Shh to 
neurogenesis in a neuroepithelium within the embryonic cerebellum called the ventricular zone 
(VZ). His finding that Shh signaling drives the expansion of cerebellar precursors in the VZ 
provided an important mechanism for understanding the genesis of the earliest born cerebellar 
GABAergic interneurons (Sotelo, 2004).  
 
I chose to follow up on Xi’s study by evaluating what role the primary cilium plays in 
transmitting the Shh signal to VZ precursor cells and did so by conditionally ablating their ciliary 
function (Figure 1.1A-B’). Initially, I was dismayed because this first wave of GABA 
neurogenesis seemed unaffected during late embryonic development following loss of cilia 
function. However, I found instead that during early neonatal development GABAergic 
precursors occupying the innermost presumptive cerebellar white matter (PWM) were greatly 
reduced in number, and this reduction occurred alongside loss of Shh pathway activity (Figure 
1.1 C-D’ and not shown). 
 
This finding excited me greatly because research from other groups indicated that the PWM 
serves as a neonatal stem niche cell where a very large second wave of GABA neurogenesis 
occurs. I looked to see whether the Shh pathway was active in the PWM and this led to my first 
significant discovery, that Shh is a key signal governing the second wave of cerebellar GABA 
neurogenesis. My study evolved to include a very intriguing delivery mechanism utilized by 
producing cells to disseminate Shh over a considerable distance. This was my second major 
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finding; that Purkinje neurons distribute Shh bi-directionally to oversee the simultaneous 
generation of spatially and functionally distinct cerebellar interneurons. These findings are 
detailed at length in CHAPTER III. 
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Figure 2.1. Deletion of VZ primary cilia identifies Shh signaling activity in the neonatal 
PWM niche.  
(A-B’) Coronal sections of WT (A, B’) and Nestin-cre; Kif3aF/- (B, B’) cerebellar VZ regions at 
e14.5. Radial glial cells express Nestin (red) and display primary cilia marked by Arl13b (green), 
which are absent in the Nestin-cre; Kif3aF/- VZ (B, B’). High magnification regions (A’, B’) 
correspond to boxed vermal VZ regions (A, B). (C-D’) Sagittal sections of PtchlacZ cerebella 
showing Shh pathway activity, represented by X-gal staining in the PWM of WT (C, C’) and 
Nestin-cre; Kif3aF/- littermates (D, D’).  
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Having gained this progress, my research took a substantial step forward, and I chose to maintain 
focus on my new favorite cell, the Purkinje neuron (PN). Early in 2010 I became fascinated by 
studies implicating the cerebellum, and importantly the PN, in the autism spectrum disorders 
(ASD) because loss of function mutations in a gene with great similarity to Ptch1 were linked to 
ASD (Noor, 2010). We chose to evaluate the expression pattern of PatchedD1 (Patched domain 
containing protein 1) in the developing cerebellum, and saw that it is mostly restricted to PNs. 
This finding led us to speculate that ectopic Shh pathway activation in PNs resulting from loss of 
PatchedD1 may lead to cerebellar cyto-architectural aberrations noted in some patients with 
autism. I chose to test this notion and activated Shh signaling cell-autonomously in PNs by 
introducing activated mutants of Smo (SmoM2) or Gli2, the major activator of Shh 
transcriptional targets (GLI2ΔN). Before any analyses could be performed, we were met with a 
very unexpected and surprising outcome, compound mutants carrying a PN-specific Cre 
recombinase, L7(Pcp2-cre), and GLI2ΔN (Figure 1.2) developed remarkably aggressive soft 
tissue tumors.  
 
This experience served as my personal introduction to the importance of accidental discovery. 
Certainly, in some cases findings like this one can be attributed to simple good fortune. 
However, I felt that we had stumbled upon a fortuitous finding because we had asked good 
questions with solid rationale, and with a well-informed scientific mind the importance of our 
discovery was quickly recognized.  
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Figure 2.2. Targeting of GLI2Δ N to cerebellar Purkinje neurons in L7(Pcp2)-cre; CLEG 
mice.  
(A-C’) Activation of the CLEG2 oncogene in postnatal cerebellar Purkinje neurons. (A) 
Schematic indicating layout of experiment and design of the CLEG2 construct; the CAG 
promoter drives ubiquitous expression of EGFP in the absence of cre recombinase, which when 
present will simultaneously delete EGFP and activate GLI2ΔN. (B-C’) Sagittal sections of 
CLEG2 (B, B’) and L7(Pcp2)-cre; CLEG2 (C, C’) adult cerebella. Purkinje neurons are marked 
by Calbindin (B’, C’), and lose EGFP expression in the presence of cre (B, B’ versus C, C’). 
IGL, internal granule cell layer; ML, molecular layer; PCL, Purkinje cell layer. Scale bars 
indicate 25 µm.   
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Though this study is described in CHAPTER IV, I will say here that I inadvertently activated 
Gli2ΔN in multi-potent mesenchymal progenitor cells using L7(Pcp2)-cre. This led to a tumor 
phenotype remarkably similar to Ewing’s sarcoma, a complicated tumor family within the soft 
tissue sarcoma spectrum, divergent in many respects from Rhabdomyosarcoma (RMS). Despite 
nearly two decades of effort, at this time no one has been able to produce a genetically inducible 
mouse model recapitulating the Ewing’s family of tumors (EFT). It seems that quite by accident 
I did, and simultaneously found that Gli2 is sufficient to induce EFT formation. Currently, the 
Ewing’s community is largely focused on EWS-FLI1, the chimeric oncoprotein resulting from a 
chromosomal translocation event found in >95% of Ewing’s cases. Our data strongly suggest 
that EWS-FLI1 binds Gli2, and likely utilizes this interaction to promote sarcomagenesis. 
Reaching this conclusion required considerable research efforts, and sustained passion to 
conquer new scientific territory. 
 
An important lesson that I learned from this process was seeing the need for being well-
informed. Unfortunately, it was not I who first recognized the discovery. Chin noticed that our 
mutants appeared to have sarcoma, which then seemed most likely to be RMS. Although I was 
familiar with cancers attributed to deregulated Shh pathway activity, RMS was one with which I 
had little familiarity. This was soon to change, but at the time my ignorance made the moment 
bittersweet. Of course I knew that something important had been found, but I was not informed 
enough on my own to truly appreciate what exactly was before me. However, I have used this 
learning experience to my benefit, and have made great strides to push forward. 
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Undoubtedly, deregulated Shh pathway function plays a greater role in sarcoma than is currently 
appreciated. Most noteworthy may be the conclusion that the level at which Shh pathway 
activation is induced determines the resulting sarcoma phenotype; whether activation occurs 
upstream at the level of Ptch1 loss of function/ Smo gain of function versus downstream at the 
level of transcriptional activator, dictates an RMS outcome versus EFT outcome. The connection 
between PNs and ASD described above, which was an unintended bridge to interests in sarcoma 
biology, has grown much stronger, and with that progress my interest in the autism field has 
thusly heightened. I will return to this connection in CHAPTER V. 
 
Though the connection between the Shh pathway and regulation of stem/ progenitor cell niches, 
particularly in the developing and adult CNS, is not new, the findings I will describe in 
CHAPTER III provided several important revelations, extending our understanding of cerebellar 
neurogenesis considerably. Similarly, the link between deregulated Shh pathway activity and the 
formation of multiple forms of cancer has been under investigation for well over a decade. 
Despite this, my work with modeling sarcoma unexpectedly yielded several surprising, and very 
new, concepts to the field, expanding upon how researchers can think about the origin of a 
scarcely understood and highly aggressive pediatric cancer. Contemplating the potential impact 
of these studies, and considering how much knowledge we continue to lack, I am very excited to 
see what more the future holds.    
   
 
 
 
	   17	  
CHAPTER III 
 
 
 
THE PURKINJE NEURON ACTS AS A CENTRAL REGULATOR OF SPATIALLY AND 
FUNCTIONALLY DISTINCT CEREBELLAR PRECURSORS 
 
 
 
 
Introduction 
 
The embryonic neuroepithelium is the origin of neuronal diversity during genesis of the 
vertebrate nervous system (Alvarez-Buylla et al., 2001). Neural stem cells (NSCs) within 
specialized regions of the brain neuroepithelium are capable of generating secondary germinal 
zones where neurogenesis continues postnatally and in some regions throughout adulthood 
(Doetsch, 2003; Merkle et al., 2004). These secondary neurogenic zones not only contribute to 
regional neuronal diversity but also maintain a steady pool of new-born neurons (Doetsch, 2003). 
However, the establishment of these niches and their maintenance in distinct postnatal 
environments is less well understood. 
 
The cerebellum provides an attractive system to study signaling mechanisms by which diverse 
cell types emerge from spatially and temporally defined niches. It has a relatively simple 
architecture, encompassing nine different neuronal subtypes that are stereotypically situated in 
distinct cortical layers: the superficial molecular layer (ML), Purkinje cell layer (PCL), internal 
granule cell layer (IGL), and the innermost white matter (WM) (Hatten and Heintz, 1995). 
Moreover, functional and anatomical evidence suggests that the cerebellum, in addition to a 
well-recognized role in motor learning and sensory control, contributes to cognitive function 
(Gillig and Sanders, 2010).  
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Neurogenesis in the cerebellum is initiated from two primary germinal neuroepithelia, the 
ventricular zone (VZ) of the fourth ventricle and the upper rhombic lip (RL). All excitatory 
glutamatergic neurons, including granule neurons, originate in the RL. The expansion of granule 
neurons is achieved through proliferation of granule cell precursors (GCPs) mediated by Shh 
during late embryogenesis and early postnatal life (Dahmane and Ruiz i Altaba, 1999; Lewis 
P.M., 2004; Wallace, 1999; Wechsler-Reya and Scott, 1999).  In contrast, the VZ gives rise to a 
subset of inhibitory GABAergic interneurons including Purkinje neurons (PNs) and deep 
cerebellar nuclei (DCN) during embryogenesis (Sillitoe and Joyner, 2007). Recent studies 
demonstrated that a transventricular Shh signaling mechanism drives the expansion of 
GABAergic progenitors in the embryonic VZ (Huang X. et al., 2010).  
 
The cerebellar VZ is also the source for precursors of the secondary germinal zone residing in 
the prospective white matter (PWM) through the first two weeks of postnatal life in mice 
(Maricich SM, 1999; Sudarov et al., 2011; Yuasa, 1996). Previous retroviral-mediated lineage 
analysis demonstrated the presence of dividing progenitors in the PWM, contributing to both 
GABAergic interneurons and astrocytes (Zhang and Goldman, 1996). These late-born 
interneurons, called stellate and basket cells, reside in the ML where they provide inhibitory 
input to PNs, the sole output neurons of the cerebellar cortex. More recent genetically-inducible 
fate mapping (GIFM) in mice showed that NSC-like ‘astroglial cells’ in the PWM robustly 
generate these late-born cell types (Silbereis et al., 2009).  
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Astroglia express prospective NSC markers such as Nestin, Sox2 and Leukocyte cluster of 
differentiation 15 (CD15), and may represent the common origin for different postnatally-born 
cerebellar cell types generated in the PWM (Silbereis et al., 2009). However, this niche also 
harbors a Prominin1 (CD133)-expressing population that is capable of self-renewal in culture 
and clonally generates neurons and glia when implanted into neonatal cerebella, and exhibits 
intrinsic region character (Klein et al., 2005; Lee et al., 2005). Therefore, it is unclear whether 
CD15 and CD133 mark common or distinct progenitors or if they are lineally related. 
Furthermore, their intrinsic developmental potentials in the PWM are unclear, as are the key 
regulatory signals and cellular mechanisms that support the remarkable neurogenic capacity of 
the PWM niche.  
 
In this study, we describe functionally divergent PWM progenitor subpopulations with 
distinctive molecular signatures that commonly respond to Shh. We found that Ptf1a+ and 
TncYFP-Low CD15+ cells, which are lineally related to TncYFP-Low CD133+ primary progenitors, 
function as intermediate progenitors that, respectively, expand postnatal precursor pools of 
GABAergic interneurons and astrocytes. Accordingly, attenuation of Shh signaling in TncYFP-Low 
cells significantly disrupts the PWM-based expansion of these precursor pools and their progeny. 
Furthermore, we found that Shh from distant PNs maintains the PWM niche, independent of, 
GCPs. Thus, PNs couple the generation of excitatory and inhibitory interneurons, facilitating 
their coordinated integration into the emerging cerebellar circuit permitting their opposing 
neuronal actions to ultimately feedback on PNs. 
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Experimental Procedures 
Animals 
All experiments were performed using young neonatal and adult animals, ages P1-P30 according 
to the NIH and VUMC Division of Animal Care. 
 
Mice of the following genetic lines, of either sex, were used: CD133-CreER (Zhu et al., 2009), 
Gli1nlacZ (Bai C.B., 2002) TncYFP-CreER (see below), Gli1CreER (Ahn and Joyner, 2004), SmoF/F 
(Long et al., 2001), Ptf1aCreER (Pan et al., 2013), ShhCre (Li et al., 2006), L7-Cre (Lewis P.M., 
2004), ShhF/F (Lewis P.M., 2001), Math1-CreERT2 (Machold R., 2005), Rosa26lacZ (Soriano, 
1999), R26ReYFP (Srinivas S., 2001), Ai9 (Madisen et al., 2010), and mT/mG  (Muzumdar et al., 
2007).  
 
Tamoxifen (Sigma) was dissolved to a final concentration of 2 mg/ ml in corn oil (Sigma). 
Postnatal CD133-CreER; Ai9, Gli1CreER; R26ReYFP, Ptf1aCreER; R26ReYFP, TncYFP-CreERT2; Ai9, 
TncYFP-CreERT2; SmoF/-, Atoh1-CreERT2; SmoF/-, Atoh1-CreERT2; R26ReYFP and wild-type 
littermates received 50 ul of tamoxifen by consecutive intraperitoneal injections on P1 and P2, or 
P3 and P4 as specified. 
 
BrdU (Roche) was dissolved in PBS to a final concentration of 10 mg/ ml and was administered 
by intraperitoneal injection. TncYFP-CreERT2; SmoF/- and wt littermates and L7-Cre; ShhF/- and wt 
littermates received a 2-hour BrdU pulse on P5 prior to sacrifice. 
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Gene targeting 
A “knock-in” strategy was used to create a Cre-recombinase mouse driven by the endogenous 
Tenascin-C promoter. The Cre transgene was engineered immediately behind the translation start 
site (ATG) of the tenascin-C gene to ensure that the expression pattern of Cre is similar to that of 
the endogenous tenascin-C gene. Mouse genomic tenascin-C gene was obtained by a BAC 
library screen (RPCI-22 mouse BAC library, Invitrogen). The targeting construct was assembled 
in pBlue (Clontech), including a 4kb 5’ arm homogenous to 5’ region upstream of the tenascin-C 
gene translation start codon in exon 2, an inducible CreER2, an IRES (internal ribosome entrance 
site)-EGFP (enhanced green fluorescence protein), a PGK-Neo selection cassette flanked by 
FRT, and a 2kb 3’ homogenous arm. The CreER2 was made from CreER version 1 (kindly 
provided by Dr. Andrew P. McMahon) via site directed mutagenesis according to the literature 
(Feil et al., 1997).  
 
The IRES-EGFP cDNA in the targeting construct allows for detecting site of Cre expression in 
mice carrying the transgene. The targeting construct was linearized by Ahd I and introduced into 
E14 129SvJ ES cells with established protocols (Tompers and Labosky, 2004) at Vanderbilt 
Mouse/ESC Shared Resource. Neo-resistant ES cell clones were screened by southern blot. 
Primers used for synthesizing 5' probe were: 5'-TAGAGCAGGTGGTCCCAAACAT-3' and 5'-
CCAGGAGCCAGGAAATAGCCTTA-3'. Primers used for synthesizing 3' probe were:  5'-
GATGACGACTACACTGGGGAA-3' and 5'-ACTGGGGCACCTTTGCTCTT-3'. Positive 
clones were picked for blastocyst injection, and germline transmission of the transgene was 
obtained. Mice heterozygous for the tenascin-C-CreER2 allele were viable and of normal size 
without significant developmental or functional abnormalities.  
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Mice were genotyped using genomic DNA isolated from tail tissue. PCR primers used to amplify 
across the region where the 5' CreER2 was inserted were: sense: 5'-
GGGGGCAAGAAGGCAAAAAT-3'; antisense-1: 5'-GTTCTGCGGGAAACCATTT-3'; 
antisense-2: 5'-TCTCGCTTGTGCCTGATGAT-3'. Primer pair of sense and antisense-1 gave a 
band of ~430bp for a targeted allele and no band for a wild type allele. Primer pair of sense and 
antisense-2 gave a band of ~300bp for a wild type allele and no band for a targeted allele.  
 
RNA isolation and reverse transcription 
Total RNA was purified from sorted cells using the RNeasy mini kit (Qiagen) and cell 
homogenization was performed using QIAshredder columns (Qiagen). cDNAs were synthesized 
with 300ng total RNA input for all samples tested using a High-Capacity cDNA reverse 
transcription kit (Applied BioSciences). PCR was performed with primers for Gli1 and GAPDH 
at 34 cycles with annealing temperature of 60oC and as previously described (Liu et al., 2013).  
 
Tissue processing and Immunohistochemistry/ Immunocytochemistry 
For animals younger than P30, brains were dissected out and fixed in 4% paraformaldehyde for 
either 4-6 hours or O/N at 4o C. Animals between P21-P30 received 50 ul intraperitoneal 
injections of Ketamine and received ice-cold PBS via transcardial perfusion followed by 4% 
paraformaldehyde. Brains were collected and submersion fixed in 4% paraformaldehyde O/N at 
4o C. These tissues were either processed for frozen embedding in OCT compound or processed 
for paraffin embedding. Frozen tissues were sectioned on a Leica cryostat at 10 um, paraffin 
embedded tissues were cut at 5 um.  
 
	   23	  
Antibodies  
Immunohistochemistry (IHC) and immunocytochemistry (ICC) were performed as previously 
described (Huang X. et al., 2010). The following primary antibodies were used to perform IHC/ 
ICC on frozen and/ or paraffin tissue sections or for flow cytometry/ FACS: chicken α-βGal 
(ICL), rabbit α-βGal (ICL), rabbit α-BLBP (Abcam), mouse α-BrdU (DSHB), mouse α-CD15 
(eBioscience, MMA), mouse α-CD15 Alexa-567 (BioLegend, MC-480), rat αCD133 PE 
(eBioscience, 13A4), mouse α-GABA (Simga), mouse α-GAD-67 (Abcam), rabbit α-GFAP 
(Abcam), mouse α-GFAP (Covance), chicken α-GFP (Aaves), guinea pig α-GLAST (Millipore), 
mouse α-Glutamate (Swant), rabbit α-Calbindin (Swant), and rabbit α-Ki67 (NeoMarkers), 
mouse α-MBP (Covance), rabbit α-Musashi (Neuromics), mouse α-Nestin (DSHB), mouse α-
NeuN (Millipore), rabbit α-Neurogranin (Millipore), mouse α-O4 (Millipore), rabbit α-Pax2 
(Invitrogen), mouse α-Parvalbumin (Sigma), rabbit α-Ptf1a (Hald et al., 2008), rabbit α-Sox2 
(Millipore), guinea pig α-Sox10 (Maka et al., 2005), chicken α-Tbr2 (Millipore) and rabbit α-
Zic1 (Chemicon). For bright-field staining, species-specific HRP-conjugated secondary 
antibodies (Invitrogen) were used followed by incubation in DAB reaction (Invitrogen). Double-
labeling fluorescence immunohistochemistry was performed using species-specific, AlexaFluor-
tagged secondary antibodies Alexa 488, Alexa 568 and Alexa 647 (Invitrogen) followed by 
counterstaining with To-pro3 iodide (Invitrogen).  
 
X-gal staining and transcript detection 
X-gal staining for β-galactosidase activity was performed on post-fixed, frozen sections 
according to standard protocols. The following cDNAs were used as templates for synthesizing 
digoxygenin-labeled riboprobes: Gli1. 
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Flow Cytometry, Neurosphere and Differentiation Assays 
Cerebella were isolated at P3, P4 or P5 from wild-type TncYFP-CreERT2 mice and were dissociated 
to single cell suspensions via microdissection and trituration in sterile PBS, then strained through 
40 µm filters. Cells were resuspended in 1% BSA and stained on ice for 30 min with primary 
antibodies, washed in sterile PBS, and resuspended with DAPI to permit exclusion of non-viable 
cells. Flow cytometry and cell sorting were performed on a FACSAria cell sorter (BD) to purify 
TncYFP-low-expressing, CD133+ or CD15+ cells. TncYFP- cerebella and forward scatter (FSC) were 
used for gating, and post-sort analysis was performed to evaluate purity of sorted cells. These 
populations were then cultured under standard neurosphere conditions in NSC medium 
[Neurobasal medium (GIBCO) supplemented with EGF (25 ng/ ml) B27 (GIBCO), N2 
(GIBCO), glutamine and Pen-Strep (Cellgro)] for 7-10 days at 37oC, 5% CO2. For quantification 
of 2o and 3 o neurosphere formation, SAG (20 nM) and KAAD-cyclopamine (4 µM) were used to 
manipulate Shh signaling.  Induction of differentiation was performed on 1o and 2o neurospheres 
derived from FACS-purified, TncYFP-low cells, which were attached to PDL-coated glass 
coverslips and cultured for 7-10 days in NSC medium (w/o EGF) containing either PDGF-aa (10 
ng/ ml) or 10% serum.  
 
Microscopy 
Bright-field images were collected on an Olympus BX51 upright microscope or on a Leica M165 
FC stereoscope. Detection of double-labeling was performed using either confocal imaging on a 
Leica TCS SP5 laser-scanning or with an Olympus fluorescent microscope outfitted with an 
Optigrid system (qioptiqimaging) for optical sectioning and MetamorphTM software (Molecular 
Devices) for image acquisition. 
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Quantifications and statistical analyses 
MetamorphTM (molecular devices) and ImageJ software were used to measure area (um2) for 
regions of interest (ROI), for acquisition of cell counts, and for surface intensity measurements. 
For each developmental stage, four ROIs were used per section. For all immunohistochemical 
stainings cell counts were obtained from a minimum of five to ten sections per brain, and all cell 
counts were normalized to area. A minimum n=3 animals was required for all genotypes at each 
stage analyzed. Sections (5 um for paraffin, 10 um for frozen) were collected in serial from 
midline regions covering 200-400 um of tissue (depending on developmental stage) along the 
medial-lateral axis. For quantification of 2o and 3o neurospheres, single cells were plated at clonal 
density (1-2 cells/ mm2) on 60 mm gridded cell culture dishes (SARSTEDT) and neurospheres 
present within a 100 mm2 area were counted. Statistical analyses were performed using Prism 
software (GraphPad). 
 
Results 
 
Shh targets distinct progenitor populations resident in the neonatal PWM  
To determine whether Shh signaling is active in the neurogenic PWM niche, we used Gli1nlacZ 
mice to assess Shh pathway activity (Bai C.B., 2002). In addition to previously reported 
expression in GCPs and Bergmann glia (Corrales JD, 2004; Lewis P.M., 2004), we observed β-
galactosidase (β-gal) expression in cells abundant throughout the lobular (but not DCN) PWM at 
P3 and P5, and observed a similar expression pattern for Gli1 mRNA, confirming activation of 
Shh signaling (Figures 3.1A-B). To ascertain the molecular identity of this Shh-responding 
population, β-gal+ cells were quantified in four regions of interest (ROI) that delineate domains 
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of lobular PWM with greatest frequency of β-gal+ cells (Figure 3.1A, R1-4).	   Because no 
significant regional variations were observed, ROI measurements were combined to generate a 
single value.  
 
We found that most β-gal+ cells expressed NSC/ astroglial markers Sox2 (75±11.8% at P3 and 
78±9.7% at P5, n=3) and BLBP (60±7.3% at P5, n=3), whereas fewer β-gal+ cells expressed cell 
cycle marker Ki67 (44±3%, n=3) or surface antigen CD15 (Figure 3.1C-F). In the early neonatal 
PWM, Shh-responding cells are numerous and represent ~one-half of total Sox2+ cells 
(54±13.2% at P3 or 47±6.6% at P5, n=3), but this signaling appears transient in nature because 
β-gal+ cells were not detected at P6 (not shown). It is important to note that neither β-gal 
expression nor concurrent cellular proliferation were observed in the cerebellar VZ (Figure 3.2 
A-A”), arguing against a contribution from that neuroepithelium in the postnatal period. These 
data indicate that PWM NSC-like astroglia actively respond to Shh in the early postnatal period. 
 
In contrast, Pax2+ GABAergic progenitors, which delineate the PWM and are largely post-
mitotic (Leto et al., 2009; Maricich SM, 1999; Weisheit et al., 2006), were negative for Shh 
signaling (Figure 3.1G, G’). However, many β -gal+ cells expressed Ptf1a (pancreatic 
transcription factor 1a) (31±4% at P3, n=3, Figure 3.1H, H’), which genetic studies have shown 
is required for GABA-lineage specification (Hoshino et al., 2005; Pascual et al., 2007). 
Following a 2-hour BrdU pulse we noted a large fraction of Ptf1a+ cells in S-phase that persisted 
at P6 (Figure 3.1I). This observation was surprising given that Ptf1a+ cells in the embryonic 
cerebellum are exclusively post-mitotic (Huang X. et al., 2010). To assess whether Ptf1a+ cells 
generate Pax2+ cells, genetically inducible fate mapping (GIFM) experiments were performed 
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using a Ptf1aCreERT2 knock-in driver (Pan et al., 2013) paired with R26ReYFP mice, to which 
tamoxifen (TM) was administered on P1 and P2. Some Ptf1a-GIFM cells proliferate in the PWM 
at P7, but most are Pax2+ (Figure 3.1J, K), confirming that Ptf1a+ cells emerge upstream of and 
contribute considerably to neonatal Pax2+ pools. These data provide a novel cellular mechanism 
supporting the rapid neonatal expansion of GABAergic progenitors pools. Long-term Ptf1a-
GIFM studies revealed exclusive marking of ML GABAergic interneurons at P30, with no 
labeling of astrocytes or other cell types at P7 or P30 (Figures 3.1L and 3.2B, C).  
 
Shh-responding cells establish progenitors of GABAergic interneurons and astrocytes 
To characterize the developmental potential of Shh-responding PWM cells, we used GIFM with 
the Gli1CreER mouse, which has been shown to efficiently label Gli1+ cells and their progeny 24 
hours following TM administration (Ahn and Joyner, 2004). TM was administered to Gli1CreER; 
R26ReYFP mice on P1 and P2 (or on P3 and P4) and the fate of YFP+ cells was determined at P5, 
P7 and P30 (Figure 3.3A). Because P3, P4 TM administration yielded lower YFP-labeling in 
marker+ populations (not shown), due to the transient nature of Shh signaling in the PWM, 
administration at P1 and P2 only was used throughout the remainder of our study. We quantified 
Gli1-GIFM cells by measuring YFP-labeling in four PWM ROI delineated by adjacent NeuN+ 
IGL granule neurons (Figure 3.4A). Because substantial regional variations in cre activity were 
not observed, measurements were combined into a single value. Labeling of Bergmann glia, a 
persistent population of Shh-responding astrocytes (Corrales JD, 2004; Lewis P.M., 2004) 
indicated our labeling efficiency was between 18% and 37% at P5 or P7, respectively (n=3) 
(Figure 3.4G, H, and J). As expected, labeling of proliferative GCPs was also observed (Figure 
3.4I). 
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Figure 3.1. Distinct progenitor populations in the neonatal PWM niche respond to Shh.  
(A-H’) Sagittal sections of Gli1nlacZ cerebella showing Gli expression, represented by either X-
gal staining (A, A’), or Gli1 mRNA in situ hybridization (B) or β-gal antibody staining (C-H’), 
in the PWM. Gli1 expression in the PWM co-localizes with NSC/astroglia markers such as Sox2 
(C), BLBP (D) and CD15 (F) as well as proliferative marker Ki67 (E) at P5. It is also expressed 
in Ptf1a+ (H, H’) but not Pax2+ (G, G’) GABAergic progenitors. (I-L) Ptf1a+ cells represent a 
proliferative population of GABAergic progenitors (I, J), and Ptf1acreERT2-GIFM analysis reveal 
that Pax2+ progenitors (K) but not GFAP+ astrocytes (L) are derived from Ptf1a+ progenitors. 
Black arrowheads indicate X-gal+ cells (A’) or Gli1 mRNA expressing cells (B), and white 
arrowheads indicate double-labeled cells. PWM, presumptive white matter. Scale bars indicate 
25 µm.  
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Figure 3.2. Shh signaling is activated in distinct PWM progenitor populations. 
(A-A”) Sagittal sections of Gli1nlacZ cerebella showing Gli1 expression as marked by βgal 
staining is not detectable in the ventricular zone (VZ) at P5. Note that cells at VZ demarcated by 
blue dotted lines are no longer proliferative (A’) but express Sox 2 (A’’). (B, C) Ptf1a-GIFM 
analysis; Ptf1aCreERT2; R26ReYFP mice received TM on P1, P2 and were analyzed at P30, 
revealing that Ptf1a+ cells generate only ML GABAergic interneurons (Parvalbumin+) but not 
astrocytes (GFAP+). Nuclei are counter-stained with To-pro3 iodide (blue). White arrowheads 
indicate double-labeled cells and dotted lines demarcate ML. Scale bars indicate 25 µm unless 
otherwise indicated.  
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Figure 3.3. PWM Shh-responding cells generate GABAergic interneurons and astrocytes.  
(A) Schematics indicating regions used for analysis of Gli1-GIFM+ cells. (B-I) Gli1CreER; 
R26ReYFP mice were injected with TM on P1 and 2 and analyzed at P5 (B, C), P7 (D, E) and P30 
(F-I). Some Gli1-GIFM+ cells highlighted by YFP expression are proliferative at P5 (B), and 
some express CD15 (C), Pax2 (D), or Ptf1a (E) in the PWM and contribute to both mature 
GABAergic interneurons (F, G) and astrocytes (H, I). (J, K) Quantitative analyses of Gli1-GIFM 
studies at P5 (J) and P7 (K) showing percentage of Gli1-GIFM+ PWM populations. Dotted line 
demarcates the PWM or ML as indicated, white arrowheads indicate double-labeled cells, and 
asterisks mark mature granule neurons. Abbreviations: IGL, internal granule cell layer; WM, 
white matter; ML, molecular layer. Scale bars indicate 25 µm.  
 
 
 
 
Į<)33D[
'
Į<)33WID
Į<)33DUY Į<)3*$'
*
Į<)3*)$3
+ ,
0/
0/
:0 ,*/(
)
0/

















*OL&UH(555H<)3
3
3
370#33DQDO\VLV#33	3
%(
)
*
+,
1HRQDWDO 0DWXUH
$
Į<)3%UG8 Į<)3&'
% &
-
.
3
RI*OL*,)03:0SRSXODWLRQV#3
RI*OL*,)03:0SRSXODWLRQV#3
	   31	  
At P5 (n=5), the majority of PWM YFP+ cells express Sox2 (52±4.3%), while the remaining 
fractions express either Ptf1a (21±5.9%) or Pax2 (31±6.9%) (Figures 3.3J and 3.4B, D). We 
also found fractions of Gli1-GIFM cells that were dividing, based on a 2-hour pulse with S-phase 
marker BrdU+, or that expressed surface antigen CD15 (Figure 3.3B, C). At P7, we detected 
more extensive YFP-labeling of marker+ populations than at P5, likely from accumulation of 
these cell types over a 48-hour period. However, the percentage of Sox2+ Gli1-GIFM cells was 
lower (32±5.5%), suggesting progression to lineage commitment with Gli1-GIFM cells 
expressing Ptf1a (23±4.2%), Pax2 (19±4.7%) and GFAP (17.3±4.4%) (n=5) (Figures 3.3D, E, K 
and 3.4E, F). We noted that Gli1-GIFM+, Pax2+ cells were abundant only within lobular PWM, 
but not in the DCN/ periventricular WM (Figures 3.3D and 3.4B, C) where a subset of 
GABAergic DCN interneurons are born during perinatal stages (Leto K, 2006; Maricich SM, 
1999).  
 
To establish the terminal fate of Gli1-GIFM cells, we evaluated the Gli1CreER; R26ReYFP 
cerebellar cortex at P30 (n=5). Consistent with the above progenitor labeling at P5-P7, abundant 
Gli1-GIFM+ cells were found in the ML positive for GAD-67 and Parvalbumin, markers of 
basket and stellate cells (Figure 3.3F, G). However, Gli1-GIFM studies did highlight two 
spatially segregated populations of astrocytes residing in the IGL and WM (Figure 3.3H, I), 
which likely represent velate protoplasmic (bushy) and smooth protoplasmic astrocytes, 
respectively (Yamada and Watanabe, 2002). However, we did not find that Gli1-GIFM cells 
contribute to MBP+ oligodendrocytes (Figure 3.4K). Collectively, these findings indicate that 
Shh-responding PWM cells possess relatively broad developmental potential and contribute to 
distinct GABAergic interneuron and astrocyte subtypes. 
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Figure 3.4. Labeling of PWM Shh-responding cells and their progeny. 
(A-K) Gli1CreERT2; R26ReYFP mice received TM on P1, P2 and were analyzed at P5 (A-D, G), P7 
(E, F, H, I), and P30 (J, K). Gli1-expressing cells and their progeny (YFP) represent a wide 
array of cell types in the cerebellum including granule neurons (A), GABAergic interneurons (B, 
C), astroglia (D, E), Bergmann glia (G, H), and astrocytes (F). Note that Gli1 lineage cells do not 
contribute to oligodendrocytes as indicated by the lack of Myelin basic protein (MBP) staining 
(K). Nuclei are counterstained with To-pro3 iodide (blue). White dotted lines demarcate the 
PWM (A) or EGL (I). Scale bars indicate 25 µm.. Abbreviations: PV-WM, periventricular white 
matter; bv, blood vessel. 
 
 
Low TenascinCYFP reporter expression marks PWM Shh-responding astroglia 
To further characterize the molecular identity and function of Shh-responding cells during the 
early neonatal period, we generated inducible TncYFP-CreER mice in which CreER and YFP are 
expressed as a bicistronic message from the endogenous TenascinC (Tnc) locus. Previous studies 
have shown that the extracellular matrix glycoprotein Tnc is expressed in glia occupying the 
neonatal cerebellar PWM (Yuasa, 1996). Our analyses indicated that TncYFP-CreER expression 
faithfully recapitulates the reported Tnc expression pattern, and revealed no TncYFP in the VZ at 
postnatal stages (Figure 3.5A-C and 3.6A, A’). 
 
Analysis with Gli1nlacZ revealed that, similar to Sox2, ~3/4 of β-gal+ cells in the PWM express 
TncYFP (74±7% at P3, n=3) (Figure 3.5A). Most TncYFP+ cells, if not all, expressed Sox2 or 
BLBP at P3 and P5 (Figure 3.5B, C), but not GABA progenitor marker Pax2 and rarely GFAP 
(Figure 3.6B, C). We performed Tnc-GIFM with TM administered to TncYFP-CreER; Ai9F/+ mice 
at P1 and P2, and analysis at P21 revealed that TncYFP+ cells, similar to Gli1+ PWM cells, 
contribute extensively to a diverse array of cerebellar cell types, including basket and stellate 
GABAergic interneurons (Parvalbumin+) and astrocytes (GFAP+) (Figure 3.5D-F).  
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We next measured the NSC attributes of TncYFP+ astroglia in vitro, and found that when cultured 
under standard neurosphere conditions, cells dissociated from cerebella of P3, P4 or P5 TncYFP-
CreER mice consistently generated 1o neurospheres (Figure 3.5I-J), all of which were positive for 
TncYFP (279/279 neurospheres). FACS was used to isolate TncYFP+ cells from 1o neurospheres 
and from freshly dissociated neonatal cerebella (Figures 3.5G, H and 3.6D-F). From the latter, 
two separate populations were distinguishable by TncYFP fluorescence intensity: a low population 
(blue peak) and a high population (red peak) (Figures 3.5H and 3.6F). The low population 
(hereafter referred to as TncYFP-low) exhibited a fluorescence peak that corresponds to that of 
enriched TncYFP+ sphere-forming cells (Figure 3.5G vs. H), indicating that sphere-forming cells 
are a distinctive subpopulation that can be readily isolated. Further analysis of TncYFP-low 
neurospheres, which exhibited capacity for extended self-renewal (i.e., up to 5o spheres), also 
revealed robust expression of numerous NSC markers (Figure 3.5K-P). The TncYFP-high cells 
likely represent Bergmann glia as they express higher level TncYFP when compared to the PMW 
astroglia in vivo (Figure 3.6G, H) and the same has been shown at the mRNA level (Yuasa, 
1996).  
 
Shh signaling promotes self-renewal in TncYFP-low cells; addition of EGF and Shh agonist SAG 
(Chen et al., 2002) exerted a synergistic effect on 2o neurosphere formation, eliciting an ~49% 
(n=3) increase in 2o neurospheres versus EGF only, and that SAG alone could not induce 
neurosphere formation (Figure 3.7A). We performed 3o neurosphere formation and again 
measured a robust Shh-mediated increase in self-renewal that correlated with expression of Gli1 
mRNA and was attenuated by Shh antagonist KAAD cyclopamine (n=3, Figure 3.7B, C). 
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Furthermore, multi-lineage differentiation capacity was tested, which showed that 3o TncYFP-low 
neurospheres can generate an extensive spectrum of cerebellar cell types based on marker 
expression for GABA (GABA, GAD-67, Parvalbumin and Neurogranin) and Glutamatergic 
lineages (Glutamate, NeuN, Tbr2 and Zic), as well as astrocytes (GFAP) and oligodendrocytes 
(O4) (Figure 3.7D-M).  
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Figure 3.5. TncYFP-low
 
expression marks Shh-responding cells capable of self-renewal in 
vitro.  
(A-C) Sagittal sections of TncYFP-creER; Gli1nlacZ cerebella at P3 showing Tnc expression as 
marked by YFP co-localizes with β-gal of Gli1 reporter (A), Sox2+ (B) and BLBP+ (C) astroglia 
markers.  (D-F) TncYFP-creER; Ai9F/+ mice were received TM on P1, P2 and were analyzed at P30. 
Tnc-expressing cells contribute both to Parv+ GABAergic interneurons (D) and GFAP+ 
astrocytes (E, F) in the cerebellum. White arrowheads indicate double-labeled cells. (G, H) 
Histograms from FACS showing YFP fluorescence intensity of dissociated TncYFP+ 2o 
neurospheres (G) or dissociated P4 TncYFP-CreER cerebella (H). Note that dissociated TncYFP-CreER 
cerebella resolves into three peaks; grey indicates cells that are negative for TncYFP, blue 
indicates low intensity corresponding to the peak derived from dissociated 2o neurospheres (G, 
H), and red is high intensity. (I-J) A 1o neurosphere derived from TncYFP-CreER P3 cerebella 
expresses YFP (I’) and NSC Sox2 (J). Bright-field view is shown in (I). (K-P) TncYFP-low-derived 
3o neurospheres express variety of NSC markers including BLBP (K), Nestin (L), Musashi (M), 
CD15 (N), Glast (O) and GFAP (P). Abbreviations: IGL, internal granule cell layer; ML, 
molecular layer; WM, white matter. Scale bars are 25 um.  
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Figure 3.6. TncYFP fluorescence intensity facilitates the enrichment of self-renewing 
astroglial cells from the neonatal PWM niche.  
(A-C) Sagittal sections of TncYFP-CreER cerebella showing the absence of Tnc expression as 
marked by YFP in VZ at P2 (A, A’) and in Pax2+ GABAergic progenitors of PWM at P5 (B). 
Tnc expression is rarely detected in astrocytes (C, white arrowhead). (D-F) FACS was performed 
on dissociated P3 wild-type cerebella (no TncYFP) (D), dissociated TncYFP+ 2o neurospheres (E) 
or dissociated P3 TncYFP-CreER cerebella (F). Dot plots show forward scatter plotted on the y-axis 
and YFP fluorescence detection on the x-axis, used to set gating for YFP+ (green) versus YFP- 
cells (black). Distinct populations from dissociated P3 TncYFP-CreER cerebella revealed by TncYFP 
fluorescence intensity (F); TncYFP- cells (black), TncYFP-low cells (blue), and TncYFP-high cells 
(red). (G) Surface plot measurement of TncYFP signal intensity using grey scale values from a 
confocal optical slice of YFP staining depicted below in H, indicating distinct TncYFP signals for 
Bergmann glia (high) and PWM astroglia (low). FCS, forward scatter. Scale bars indicate 25 µm. 
 
 
Distinct Shh-responding astroglial subpopulations are revealed by TncYFP-low expression 
Because Shh-responsive, TncYFP-low cells display attributes of cerebellar NSCs, we tested them 
for expression of CD133, an established NSC marker in the postnatal cerebellum (Lee et al., 
2005). We found that only a small fraction of TncYFP-low cells express CD133 at P3 using flow 
cytometric analysis (<0.5%) (Figure 3.7N, boxed in Q2). Given that a subset of Shh-responding 
cells also express NSC-associated surface antigen CD15 (Figure 3.1F), the distribution of 
CD133 and CD15 was evaluated amongst TncYFP-low cells (Figure 3.7N, blue population). This 
combinatorial marker analysis clearly distinguished astroglial subpopulations at P5 that are either 
1) TncYFP-low CD133+ (gold), 2) TncYFP-low CD15+ (purple), or 3) TncYFP-low CD133- CD15- (blue) 
(Figure 3.7O, <2.5%, <0.5% or >97%, of TncYFP-low cells, respectively). Consistent with our 
above data we found that TncYFP-low CD15+ cells exhibit Shh pathway activation as measured by 
Gli1 expression, but also found that TncYFP-low CD133+ cells respond to Shh (Figure 3.7P). 
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We next evaluated the respective NSC attributes of the above three TncYFP-low astroglial 
subpopulations in vitro, as well as the top 20% of TncYFP-high cells. Consistent with previous 
studies (Lee et al., 2005), TNCYFP-low CD133+ cells generated neurospheres, but, to our surprise, 
so did TncYFP-low CD15+ cells, TncYFP-low CD133- CD15- cells, and TncYFP-high cells, which 
expressed the same gamut of NSC markers (Figure 3.8A-L). Similar to previous studies, we 
observed progressively limited self-renewal with each passage (1/16-1/27 neurospheres/ cells 
plated)(Lee et al., 2005). However, when subjected to multi-lineage differentiation, all CD133- 
astroglial subpopulations predominantly generated astrocytes and displayed very limited 
neurogenic potential with no apparent GABA or glutamatergic marker expression (Figure 3.8M-
Q). These findings suggest that all CD133- cells are restricted progenitors lacking the full 
repertoire of NSC characteristics. Collectively, our data indicate the PWM is comprised of 
multiple Shh-responding, functionally and antigenically divergent progenitors, and distinguishes 
previously unappreciated astroglial subpopulations.  
 
Shh maintains PWM proliferation and GABAergic progenitor expansion  
We next sought to determine the specific requirement for Shh signaling in TncYFP-low cells in vivo 
during the early neonatal period. Because Shh signaling is required for the proliferation of radial 
glial cells in the cerebellar VZ during embryogenesis (Huang X. et al., 2010), we decided to use 
inducible TncYFP-CreER mice to temporally ablate Shh-responsiveness in the PMW. To gauge Shh-
responsiveness in the PWM following Smoothened (Smo) deletion with consecutive TM 
administrations on P1 and P2, we utilized the Gli1nlacZ reporter strain and noted qualitatively 
fewer β-gal+ cells at P3 and P4 in PWM of TncYFP-CreER; Gli1nlacZ ; SmoF/- mice versus littermate 
controls (Figures 3.9A, B and 3.10A, B). At P5, TncYFP-low cells were isolated from cerebella of 
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wild-type TncYFP-CreER and TncYFP-CreER; SmoF/- littermates using FACS, and RT-PCR for Gli1 
mRNA confirmed attenuation of Shh signaling in mosaic mutant TncYFP-low cells (Figure 3.10C, 
D).  
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Figure 3.7. Shh promotes self-renewal of multi-potent TncYFP-low
 
astroglia, which include 
molecularly distinct subpopulations.  
(A-B) 2o (A) and 3o (B) neurospheres were generated from TncYFP-low cerebella and neurosphere 
formation were quantified following treatment with 25ng/ml EGF alone, 20nM SAG w/ EGF, 
10nM KAAD cyclopamine w/ EGF or SAG alone for 10 days (n=3). SAG significantly 
augmented neurosphere-forming capacity of EGF. Additionally, neurosphere formation is 
dependent on Shh signaling as Smo inhibitor KAAD-cyclopamine inhibited neurosphere 
formation (B). (C) RT-PCR for Gli1 and GAPDH using total RNA from treatment groups in B. 
(D-M) TncYFP-low-derived 2o neurospheres can differentiate into diverse array of cell types 
including glutamatergic neurons (D-G), GABAergic neurons (I-L), oligodendrocytes (H) and 
astrocytes (M) when exposed to serum or PDGF for 10 days. Glutamate (Glut), Tbr2, NeuN and 
Zic1 are markers of glutamatergic neurons; GABA, GAD-67, Neurograinin (Neuro) are markers 
of GABAergic neurons; O4 and GFAP are markers of oligodendrocytes and astrocytes, 
respectively. (N-O) Dot plot from FACS analysis showing distribution of CD133+ cells amongst 
all TncYFP cells at P3 (N), and distribution of CD133+ and CD15+ cells in the TncYFP-low 
population at P5 (O). Note that TncYFP-low, CD133+ cells (boxed) represents < 0.5%.  (P) Gli1 is 
expressed in both TncYFP-low, CD133+ and TncYFP-low, CD15+ subpopulations as indicated by RT-
PCR. GAPDH was used as an internal control and e10.5 limb bud was used as a positive control 
for Gli1 expression. Error bars are presented as SEM, and p value relative to control samples 
indicated. Scale bars indicate 25 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
	   43	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Molecularly distinct TncYFP subpopulations generate neurospheres but exhibit 
limited differentiation potential. 
(A-L) NSC marker Sox2 (A, E, I), BLBP (B, F, J), CD15 (C, G, K) and Nestin (D, H, L) 
expression by 3o neurospheres derived from three distinct, FACS-purified TncYFP, CD133- 
populations; (i) TncYFP-low CD15+ CD133- (A-D), (ii) TncYFP-low CD15- CD133- (E-H) and (iii) 
TncYFP-high (I-L).  (M-Q) Forced differentiation of 3o neurospheres derived from the above-
mentioned populations with serum or PDGF-aa for 10 days. Note that all CD133- astroglial 
subpopulations predominantly generated astrocytes and displayed very limited neurogenic 
potential with no apparent GABA or glutamatergic marker expression. Scale bars indicate 25 
µm. 
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We first focused our analysis on the extensive cellular proliferation occurring in the PWM at P5 
following a 2 hour BrdU pulse, at which time presumably one-half of the GABA progenitor pool 
has been born (Weisheit et al., 2006). A large fraction of acutely dividing cells in normal 
cerebellum are Sox2+ (Figure 3.9C, C’), and consistent with our finding that Shh stimulation 
can enhance the sphere-forming capacity of TncYFP-low cells (Figure 3.7A, B), there was a 
significant reduction in the fraction of dividing Sox2+ cells in the PWM of the TncYFP-CreERT2; 
SmoF/- cerebellum (ROI I: 28.92%, ROI II: 19.55%, ROI III: 18.24%, ROI IV: 29.73%, n=3) 
(Figure 3.9C-D’, M). Reductions in proliferation were not accompanied by increased cell death 
(Figure 3.10E).  
 
Subsequent analyses were focused on Ptf1a+ and Pax2+ cells in PWM between P5-P7, by which 
time the majority (75%) of the latter have been born (Weisheit et al., 2006). Reductions were 
apparent in these populations at P5 and P7, respectively (ROI I: 35%, ROI II: 18%, ROI III: 
44%, ROI IV: 69%, n=3 and ROI I: 31%, ROI II: 30%, ROI III: 23%, ROI IV: 29%, n=4) 
(Figure 3.9E-H, N, O). When total Pax2+ cell number was measured (versus the regional 
number above), it was considerably reduced (18.31%, n=4), precluding that a failure in migration 
of Pax2+ cells contributed to reductions in regional pools (Figure 3.9P). 
 
Additionally, the Ai9F/+ reporter strain was used to more closely approximate the contribution of 
the Tnc-lineage to PWM Pax2+ progenitor pools under normal conditions (TncCreERT2; Ai9F/+) 
and attenuated Shh signaling (TncCreERT2; Ai9F/+; SmoF/-). Indeed, ablation of Smo disrupted the 
capacity of TncYFP-low cells for generating GABAergic precursors; TncYFP-CreER; Ai9F/+; SmoF/- 
cerebella had substantially reduced Pax2+, tdTomato+ (62.4%) and Ptf1a+, tdTomato+ (33%) 
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double-positive cells at P7 (per 20 um2 of PWM) (Figure 3.9I, J and 3.10F, G). The reduction in 
Pax2+, tdTomato+ cells is unlikely due to lower recombination efficiency of the reporter in 
mutant cells because similar numbers of tdTomato+, TncYFP+ double-positive Bergmann glia are 
observed between control and mutant (89.8±1% versus 92.1±0.8%, Figure 3.105H). However, 
such extensive labeling of internal control cells likely over-estimates Smo deletion. Consistent 
with reduced Pax2+/ Ptf1a+ cells, we observed a substantial loss (30.6%) of basket and stellate 
GABAergic interneurons at P30 (per 20 um2 of ML) (Figure 3.9K, L, Q) Collectively, these 
data demonstrate the importance of Shh signaling for the establishment of a neurogenic niche in 
the PWM.  
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Figure 3.9. Shh signaling supports proliferation and expansion of GABAergic interneuron 
progenitors in PWM domains.   
(A-L) Analysis of TncYFP-CreER and TncYFP-CreER; SmoF/- cerebella from mice injected with TM on 
P1, P2 and analyzed at P3 (A, B), P5 (C-F), P7 (G-J) or P30 (K, L) with either the Gli1nlacZ (A-
H) or Ai9F/+ (I-L) reporter. Gli1 expression as detected by X-gal is reduced in PWM of P3 
TncYFP-CreER; SmoF/- Gli1nlacZ; SmoF/- cerebella when compared to the control TncYFP-CreER; 
Gli1nlacZ (A, B). Similarly, Brdu+ Sox2+ (C-D’), Ptf1a+ (E, F), Pax2+ (G, H, I, J) and Parv+ (K, L) 
cells are also significantly reduced in the mutants. (M-Q) Quantitative analyses of BrdU+, Sox2+ 
cells over total Sox2+ cells (M), Ptf1a+ cells (N), Pax2+ cells (O), total Pax2+ cells (P) and Parv+ 
cells (Q) in TncYFP-CreER (grey bar) and TncYFP-CreER; SmoF/-  (open bar) cerebella. All the analyses 
were performed on 5 to 10 sections per brain and with three or four animals per genotype. Error 
bars are presented as SEM, and p value relative to control samples indicated. White dotted lines 
demarcate the PWM, white arrowheads indicate double-labeled cells. Scale bars indicate 25 µm.  
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Figure 3.10. Attenuation of Shh pathway activity after Smo ablation in TncYFP-low cells. 
(A, B) X-gal detection for β-galactosidase activity in PWM of P4 TncYFP-CreER; Gli1nlacZ or 
TncYFP-CreER; Gli1nlacZ; SmoF/- cerebella from mice that received TM on P1, P2. Gli1 expression 
as detected by X-gal is reduced in PWM of P4 TncYFP-CreER; SmoF/- Gli1nlacZ; SmoF/- cerebella (B) 
when compared to the control TncYFP-CreER; Gli1nlacZ (A). (C) TncYFP fluorescence intensity from 
FACS; dot plots of dissociated P5 cerebella from SmoF/+, TncYFP-CreER, and TncYFP-CreER; SmoF/- 
mice that received TM on P1 and P2. Forward scatter is plotted on the y-axis and YFP detection 
is on the x-axis. Black color indicates cells regarded as TncYFP-, blue indicates TncYFP-low, and red 
indicates TncYFP-high status. (D) Attenuation of Shh-responsiveness was evident in SmoF/- mutant, 
TncYFP-low cells indicated by RT-PCR for Gli1. GAPDH was used as an internal control. (E) 
Quantitative analysis of cleaved-caspase 3 (CC3)+ cells in TncYFP-CreER (grey bar) and TncYFP-
CreER; SmoF/-  (open bar) cerebella indicated cell viability is not compromised in the PWM 
following Smo ablation. (F-H) Cerebella from TncYFP-CreER; Ai9F/+ (grey bar) and TncYFP-CreER; 
SmoF/-; Ai9F/+ (open bar) mice that received TM on P1, P2 and were analyzed at P7 for (F) 
Pax2+, tdTom+, (G) Ptf1a+, tdTom+ cells, and (H) TncYFP+, tdTom+ Bergmann glia. All the 
analyses were performed on 5 to 10 sections per brain and with three or four animals per 
genotype. Error bars are presented as SEM, and p value relative to control samples indicated. 
Scale bars indicate 25 µm unless otherwise stated. FCS, forward scatter. 
 
Shh promotes expansion of CD15+ astrocyte precursors in lobular PWM domains 
Because TncYFP-low CD15+ cells were overwhelmingly gliogenic in vitro (Figure 3.8) we sought 
to further evaluate their developmental potential in vivo. Although flow cytometry indicated that 
CD15+ cells represent a small fraction of TncYFP-low cells at P5 (<0.5%) (Figure 3.7O), we found 
broad distribution of CD15 in the lobular PWM at P7. We first examined whether CD15 marks 
oligodendrocytes or their precursors at the latter stage. We did not find convincing co-expression 
with MBP, which was largely restricted to core PWM (DCN) near the 4th ventricle (Figure 
3.11A, A’). Analysis of oligodendrocyte precursor cell marker Sox10 (Stolt et al., 2002) showed 
no definitive overlap with CD15 in neither core nor lobular PWM (Figure 3.11B, C), and 
revealed that Sox10+ cells persist in the PWM of TncYFP-CreER; SmoF/- mutants (Figure 3.11B, C 
versus D, E). These data are consistent with our Gli1-GIFM, which indicated Gli1+ cells do not 
generate oligodendrocytes in the postnatal period, and with previous transplantation and chick-
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quail chimeric studies that showed cerebellar OPCs largely arise from extracerebellar regions 
during embryogenesis (Grimaldi et al., 2009; Mecklenburg et al., 2011). 
 
However, this analysis did reveal that expansion of CD15+ cells in lobular PWM is heavily 
dependent on Shh signaling: in TncYFP-CreER; SmoF/- mutants CD15+ cells fail to accumulate in 
these regions (Figure 3.11B versus D). Interestingly, we found frequent co-expression between 
CD15 and GFAP (Figure 3.11F), suggesting that TncYFP-low CD15+ cells may be intermediate 
astrocyte precursors. These data demonstrate the importance of Shh activity we detected earlier 
in β-gal+, CD15+ cells in Gli1nlacZ cerebella (Figure 3.1F) and in FACS-purified TncYFP-low 
CD15+ cells at P5 (Figure 3.7P). Because we did not observe β -gal+ cells in the core PWM in 
Gli1nlacZ cerebella (at either P3, P5 or P6), we were not surprised to find that CD15 expression 
there was largely unaffected in TncYFP-CreER; SmoF/- mutants (Figure 3.11C versus E). However, 
in lobular PWM at P7 the accumulation of GFAP+ cells was markedly reduced (37% overall, 
n=3) in TncYFP-CreER; SmoF/- mutants (Figure 3.11F versus H and G versus I, J), implicating Shh 
as a major driver in the generation of cerebellar astrocytes via a TncYFP-Low CD15+ intermediate 
progenitor.  
 
To assess whether CD15+ PWM cells descend from a CD133+ primary progenitor, CD133-GIFM 
with TM administered to CD133-CreER; Ai9F/+ mice at P1 and P2 was performed. At P7 that 
PWM CD15+ cells have descended from a CD133+ parent population, similar to astrocytes and 
Pax2+ cells (Figure 3.11K-M). Additionally, at P21, CD133-GIFM cells generate many 
cerebellar cell types, including ML GABAergic interneurons and various astrocyte populations 
(Figure 3.11N, O). However, we never observed that CD133-GIFM cells contribute to 
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Bergmann glia, which are born prior to E14.5 (Sudarov et al., 2011) (Figure 3.11P). These data 
support a lineage relationship between TncYFP-low CD133+ primary progenitors with intermediate 
astrocyte precursors (TncYFP-low CD15+) and transient amplifying GABAergic progenitors 
(Ptf1a+) 
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Figure 3.11 Shh signaling promotes expansion of CD15+ intermediate astrocyte precursors, 
lineally related to CD133+ PWM neuronal stem cells. 
(A-I) Control TncYFP-CreER (A-C, F, G) and mutant TncYFP-CreER; SmoF/  (D, E, H, I) mice were 
injected with TM on P1, P2 and cerebella were stained with CD15 (A-F, H), Sox10 (B-E) and 
GFAP (F-I) at P7. CD15 expression is broadly distributed in the core and lobular PWM (A, B) 
and does not represent oligodendrocytes as revealed by the lack of co-localization with MBP 
(A’) or Sox10 (C) expression. In TncYFP-CreER; SmoF/- mutants, only the lobular (B, D) but not the 
core (C, E) CD15 expression is drastically reduced, whereas Sox10 expression remains 
unaffected (C, E). Accordingly, the expression of astrocyte marker GFAP is reduced in the 
mutants (F-I). Red dotted lines in G and I indicate PWM. (J) Quantitative analysis of GFAP+ 
cells in TncYFP-CreER (grey bar) and TncYFP-CreER; SmoF/- mutant (open bar) cerebella. All the 
analyses were performed on 5 to 10 sections per brain and with four animals per genotype. Error 
bars are presented as SEM, and p value relative to control samples indicated. (K-P) Lineage 
analysis of CD133+ cells in the cerebellum. CD133-CreER; Ai9F/+ mice received TM on P1 and 
P2, analyzed at P7 (K-M) and P21 (N-P). CD133+ cells contribute broadly to diverse cell types 
including CD15+ precursors (K), GFAP+ astrocytes (L, N), Pax2+ progenitors (M) and Parv+ 
GABA interneurons (O, P). Asterisks indicate endothelial cells. Scale bars indicate 25 µm.  
 
 
PN-derived Shh signals distantly to maintain the PWM niche  
We previously reported that CSF-derived Shh promotes radial glial proliferation in the 
embryonic cerebellar VZ (Huang X. et al., 2010). Though it is unlikely this transventricular 
signaling could reach the lobular PWM, cerebellar PNs express Shh and extend axons deep into 
the cortex by the end of embryogenesis (Lewis P.M., 2004; Sillitoe et al., 2009). Our analysis 
with ShhCre; mT/mG mice clearly indicated PN axons descend through PWM at P3 (Figure 
3.12A). These projections bring PNs into close proximity with otherwise distant Sox2+ cells 
(Figure 3.12B), suggesting a plausible means of disseminating Shh over this distance. Indeed, 
we were able to detect puncta of Shh ligand distributed throughout the lobular PWM at P3-P4, in 
a pattern similar to that observed in the EGL, while the strongest signal was concentrated around 
the soma of Shh-producing PNs (Figure 3.12C-D’). 
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To determine if Shh produced by PNs does indeed activate Shh signaling to maintain the PWM 
niche, Shh signaling in PMW cells was robustly blocked using the PN-specific L7-Cre transgenic 
driver to remove Shh function starting at e17.5, without affecting embryonic VZ function (Lewis 
P.M., 2004). We analyzed L7-Cre; ShhF/-; Gli1nlacZ cerebella and observed a dramatic loss of Shh 
signaling as evidenced by considerable loss of PWM β-gal+, Sox2+ (double-positive) cells 
compared to Gli1nlacZ littermates (Figure 3.12E versus F). Accordingly, the fraction of S-phase 
Sox2+ cells was significantly reduced in L7-Cre; ShhF/- PWM at P5 (ROI I: 25%, ROI II: 47%, 
ROI III: 29%, ROI IV: 28%, n=3) (Figure 3.12G’ versus I’, K). These results indicate that PN-
derived Shh ligand strongly supports a proliferative compartment in the PWM. 
 
We next evaluated the capacity of PN-derived Shh to promote neurogenesis by measuring local 
Pax2+ populations within the PWM. Indeed, these progenitors were considerably reduced in L7-
Cre; ShhF/- mice at P5 (ROI I: 25%, ROI II: 47%, ROI III: 29%, ROI IV: 28%, n=3) (Figure 
3.12H versus J, L). This aberration was even more pronounced for total Pax2+ cell number, 
which was dramatically reduced (46.15%, n=3, Figure 3.12M). These changes were not 
accompanied by increases in cell death. In fact, decreases in cell death were evident, possibly 
due to the substantial loss of GABAergic progenitors (46.15%), some of which are known to 
normally undergo cell death in the PWM (Yamanaka et al., 2004). 
 
PN-derived Shh supports the generation of multiple GABAergic interneuron subtypes  
Birth-dating studies have shown that PNs are generated early, from E10.5 to E12.5, whereas 
GABAergic interneurons are generated during late embryogenesis through the first week of 
postnatal life (Altman J, 1997). Consistent with this observation, PN number is largely 
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unaffected in L7-Cre; ShhF/- mutants (Lewis P.M., 2004) whereas the number of Parvalbumin+ 
basket and stellate cells in the ML was significantly reduced at P30 (Figure 3.12N and 3.13A, B 
versus C, D). Interestingly, an earlier-born GABAergic interneuron subtype, Golgi cells, which 
reside in the IGL and selectively express Neurogranin, were also reduced (Figure 3.13E, F 
versus G, H, J). We did not find that Golgi cells were marked by our Gli1, Ptf1a, Tnc, or 
CD133-GIFM experiments, likely owing to the proposed perinatal birth-date for this cell type 
(Sudarov et al., 2011). These results indicate that PN-derived Shh is a common driver for the 
generation of numerous GABAergic interneuron subtypes.   
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Figure 3.12. Purkinje neuron-derived Shh signals distantly to maintain the PWM niche. 
  (A, B) Sagittal sections of P3 ShhCre; mT/mG cerebella showing PN cell body (Calbindin), PN 
axons (YFP) and astroglia (Sox2) in the PWM. (C-D’) Distribution of Shh protein (green) in 
PWM and EGL of P3 sagittal cerebellar sections. Nuclei are counterstained with To-pro3 iodide 
(blue). Note that Shh protein is concentrated around the PN soma (white arrowheads). (E, F) Shh 
signaling as revealed by β-galactosidase antibody staining is significantly reduced in L7-cre; 
ShhF/-; Gli1nlacZ mutant cerebella when compared to of control ShhF/+; Gli1nlacZ at P5. Inner white 
dotted line demarcates PWM, whereas outer dotted line indicates Bergmann glia. (G-J) In 
contrast to control, L7-cre; ShhF/- mice show drastic reduction of proliferating Sox2+ cells (G, 
G’, I, I’) and Pax2+ progenitors (H, J) at P5 following a 2hr BrdU pulse. Staining for markers 
indicated. PWM is delineated by white dotted lines (G, G’, I, I’) and red dotted lines (H, J). (K-
N) Quantitative analyses of BrdU+, Sox2+ cells (K), Pax2+ cells (L, M) and Parv+ cells (N) in L7-
cre (grey bar) and L7-cre; ShhF/- (open bar) cerebella. All the analyses were performed on 5 to 
10 sections per brain and with three animals per genotype. Error bars are presented as SEM, and 
p value relative to control samples indicated. Red dotted lines demarcates the PWM. Scale bars 
indicate 25 µm. PWM, presumptive white matter.  
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Figure 3.13 Paucity of mature GABAergic interneurons results from loss of PN-derived 
Shh. 
(A-H) Sagittal sections of cerebella from control (A, B, E, F) and L7-Cre; ShhF/- (C, D, G, H) 
littermates, showing reduced numbers of GABAergic inhibitory interneurons at P30. Staining for 
Parvalbumin (A-D) and Neurogranin (E-H). (I) Schematic indicating regions used for analysis of 
ML (red boxes) or IGL (green boxes). (J) Quantitative analysis of internal granule layer (IGL) 
Golgi inhibitory interneurons. All the analyses were performed on 5 to 10 sections per brain and 
with three or four animals per genotype. Error bars are presented as SEM, and p value relative to 
control samples indicated. Scale bars indicate 25 µm. Abbreviations: CB, cerebellum; MB, 
midbrain; ML, molecular layer. 
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Postnatal expansion of GABAergic progenitors is independent of cerebellar growth  
Because deletion of Shh from PNs substantially disrupts cortical expansion of the cerebellum 
(Lewis P.M., 2004), this approach could impair neurogenesis in the PWM indirectly via 
reduction of GCPs. To resolve this issue, we ablated Shh-responsiveness specifically from 
proliferative, Atoh1-expressing GCPs by TM administration at P1 and P2 (Figure 3.14A, A’) 
and analyzed local Pax2+ pools at P7. First, as expected, the Atoh1-CreER; SmoF/- EGL exhibited 
substantially less proliferation (Figure 3.14B, B’ versus D, D’). However, despite severe 
cerebellar hypoplasia (Figure 3.14C versus E), Pax2+ cell numbers were not decreased (n=3, 
Figure 3.14C, C’ versus E, E’ and F). Together our findings indicate that GABA neurogenesis 
in the PWM is not linked to expansion of GCPs and global cerebellar growth, and that it 
proceeds normally when the latter processes are disrupted. 
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Figure 3.14 Cerebellar hypoplasia does not affect GABA neurogenesis in the PWM niche. 
(A, E’) Analysis of Atoh1-creERT2; R26ReYF (A-A’), Atoh1-creER (B-C’) and Atoh1-creER; 
SmoF/- (D-E’) cerebella from littermates injected with tamoxifen at P1, P2 and analyzed at P7. 
(A-A’) Sagittal section of Atoh1-creERT2; R26ReYF showing efficient recombination in the EGL. 
(B-D’) Number of Ki67+ cells in the EGL (B, B’, D, D’) but not Pax2+ progenitors (C, C’, E, E’) 
are drastically reduced in Atoh1-creER; SmoF/- when compared to Atoh1-creER control. (F) 
Quantification of regional Pax2+ cells shows the development of GABAergic interneuron 
progenitors are not affected in Atoh1-creER; SmoF/- mutants. Red dotted lines demarcate the 
PWM. Scale bars indicate 25 µm unless otherwise stated. Error bars are presented as SEM, and  
p value relative to control samples indicated. (G) Model of postnatal cerebellar neurogenesis. By 
sending Shh bi-directionally, Purkinje neurons (PN) simultaneously modulate the numbers of 
both excitatory and inhibitory interneurons, which originate in distant, spatially segregated 
progenitor domains.  This model posits that the neonatal PWM niche is comprised of lineally-
related, but molecularly and functionally divergent progenitor subpopulations, which descend 
from a TncYFP-low CD133+ primary progenitor. Within this niche, we show that Ptf1a+ 
GABAergic progenitors and TncYFP-low CD15+ astrocyte precursors are proliferative. This model 
was conceived based on clonal analysis of CD133+ PWM cells transplanted into neonatal 
cerebella (Lee et al., 2005) in combination with our own fate-mapping of Gli1+, Ptf1a+, Tnc+, 
and CD133+ cells. GCP denotes granule cell precursors.  
 
 
Discussion 
The work presented here demonstrates that the PWM niche contains molecularly distinct 
subpopulations with divergent developmental potentials (broad lineage, neurogenic and 
astrocytic). These progenitor subpopulations commonly respond to Shh, which robustly 
promotes the propagation of their respective progeny. Finally, we found that PN-Shh maintains a 
bi-directional signaling axis that simultaneously promotes EGL-based cortical expansion and 
maintenance of the PWM niche. These results, together with previous studies, demonstrate that 
PNs are a central signaling node, modulating both inhibitory and excitatory neuronal cell 
numbers. Perturbations to the generation of these functionally distinct subpopulations as the 
result of PN dysfunction may have important implications for human neurodevelopmental 
disorders rooted in excitatory/ inhibitory imbalance.  
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Shh signals to molecularly and functionally distinct populations of PWM progenitor cells 
Previous studies have suggested that astroglia marked by human GFAP promoter activity in the 
postnatal cerebellum contribute to both neurons and astrocytes (Silbereis et al., 2009). Our 
studies suggest that these astroglia are the major Shh-responding population in the PWM, 
whereas the cerebellar VZ no longer responds to Shh and is mitotically inactive. These astroglia 
not only express markers characteristic of NSCs, but their descendents, analyzed through Gli1-
GIFM analysis, contribute broadly to cerebellar architecture, generating distinct GABAergic 
interneuron as well as astrocyte subtypes. Shh-responding astroglia are heterogeneous as they 
can be sorted into two populations based on TncYFP reporter levels. As shown previously for Tnc 
mRNA expression (Yuasa, 1996), TncYFP is expressed in both PCL and PWM, but not in the 
postnatal cerebellar VZ (Figure 3.6A, A’). The majority of glial cells associated with TncYFP-high 
likely represent Bergmann glia, as they are the most abundant glial population expressing strong 
Tnc. Indeed, the TncYFP expression profile in cerebellar sections indicated that fluorescence 
intensity is much higher in Bergmann glia than in PWM astroglia (Figure 3.6G, H). 
 
The TncYFP-low population can be further separated into three molecularly distinct subpopulations 
based on expression of NSC-associated surface antigens, CD133 and CD15. We found that The 
TncYFP-low CD133+ cells are the most broadly potent Shh-responding population in the PWM. 
These primary progenitors and their descendent cells, analyzed through Gli1, Ptf1a, Tnc, and 
CD133-GIFM analyses, contribute broadly to cerebellar architecture, generating distinct 
GABAergic interneurons and astrocytes. TncYFP-low CD133+ cells display the full repertoire of 
NSC attributes, similar to CD133+/ lineage- NSCs (Lee et al., 2005). Unlike these previously 
reported cerebellar NSCs (Lee et al., 2005), we found that Shh signaling and EGF synergize to 
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promote self-renewal of TncYFP-low cells, similar to the synergism of Shh - EGF reported for 
postnatal SVZ NSCs (Palma et al., 2005). 
 
Unlike TncYFP-low CD133+ cells, both TncYFP-low CD15+ and TncYFP-low CD133- CD15- 
populations gave rise predominantly to astrocytes in culture. Collectively, our data (including 
CD133-GIFM) along with clonal analysis of CD133+/ lineage- NSCs (Lee et al., 2005), suggest 
these latter populations represent stages along a progenitor lineage derived from more broadly 
potent TncYFP-low CD133+ primary progenitors (Figure 3.14G). However, additional in vivo 
clonal analysis is required to demonstrate that intermediate astrocyte (TncYFP-low CD15+) and 
GABAergic interneuron (Ptf1a+) precursors are derived from a common Gli1+ TncYFP-low 
CD133+ astroglial primary progenitor.  
 
The neurosphere-forming capacity of TncYFP-low CD133- populations was unanticipated but is not 
surprising, because restricted progenitors can also generate neurospheres in vitro (Kondo and 
Raff, 2000; Temple, 2001). Our work indicates that TncYFP-low CD15+ cells are intermediate 
astrocyte precursors, and are functionally divergent from CD15+ cells in the EGL (Ashwell and 
Mai, 1997; Read et al., 2009). Given that CD15 marks NSCs in the embryonic and adult SVZ 
(Capela and Temple, 2002; Solter and Knowles, 1978), our observation that TncYFP-low CD15+ 
cells are restricted progenitors was somewhat unexpected, providing insight into the function of 
CD15+ cells in other neurogenic niches.  
 
Though TncYFP cells display two distinct reporter levels, TncYFP-high Bergmann glial cells are 
spatially isolated from the proliferative PWM niche and lack CD133 expression. Additionally, 
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TncYFP, similar to Tnc mRNA (Yuasa, 1996), is not expressed in the postnatal cerebellar VZ 
(Figure 3.6A, A’). Thus, TncYFP-low cells are the only relevant population in the context of 
neurogenesis/ gliogenesis occurring in the postnatal PWM. Unlike Bergmann glia, these TncYFP-
low cells respond to Shh only transiently, suggesting Shh signaling is actively inhibited after P6. 
Recently, it was shown that Wnt signaling is activated in the PWM at postnatal stages 
(Selvadurai and Mason, 2011) and when ectopically activated Wnt signaling disrupts self-
renewal in neonatal CD133+/ lineage- NSCs (Pei et al., 2012). Therefore, it is possible that Wnt is 
antagonistic to Shh activity in the PWM, analogous to that proposed elsewhere for cerebellar 
GCPs (Lorenz et al., 2011). 
 
Ptf1a marks transient amplifying progenitors of GABAergic interneurons 
Late–born GABAergic interneurons are estimated to represent ~90% of all inhibitory 
interneurons in the cerebellum, and the majority of their progenitors, marked by Pax2 expression, 
are generated during the first week of postnatal life (Weisheit et al., 2006). Recent studies have 
shown that Pax2 expression is upregulated at the final progenitor cell division (Leto et al., 2009; 
Weisheit et al., 2006), and thus, a mechanism must exist to account for the vast numbers of 
Pax2+ cells generated during this brief window. Although Pax2+ cells can be traced to astroglia 
(Silbereis et al., 2009), it is unlikely that proliferation of astroglia alone is sufficient to expand 
the vast Pax2+ pools. Our analyses demonstrated not only that Pax2+ cells descend from Ptf1a+ 
cells, but also that the latter are transient, intermediate progenitors that appear to drive the rapid 
expansion of Pax2+ pools. This role for Ptf1a is distinctly different from its previously reported 
function in GABA lineage allocation, in which it acts to potently suppress glutamatergic fate 
(Hoshino et al., 2005; Pascual et al., 2007). 
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Purkinje neurons are a bi-directional signaling center  
PNs are recognized by elaborate dendritic arbors, through which Shh is likely disseminated to 
the EGL, driving transient proliferation of GCPs (Lewis P.M., 2004). Our present study indicates 
that Shh from PNs is also necessary for maintenance of the distant PWM niche, where we 
propose that it targets distinct progenitor populations, including TncYFP-low CD133+ primary 
progenitors, Ptf1a+ GABA-intermediate and TncYFP-low CD15+ astrocyte-intermediate progenitors 
(Figure 3.14G). While PNs are a common source of Shh ligand for both the EGL and PWM, our 
study indicated that direct perturbation of GCP proliferation did not impact GABAergic 
progenitor expansion, suggesting that cortical growth has little (if any) immediate impact on 
maintenance of the PWM.  
 
Several recent studies suggested an atypical mode of Shh delivery to target sites, utilizing axons 
as a vehicle (Brownell et al., 2011; Garcia et al., 2010; Ihrie et al., 2011; Traiffort et al., 2001). 
This delivery mechanism was first noted in Drosophila in which Hh is transported along retinal 
axons to the brain (Huang and Kunes, 1996). Our study suggests a similar mechanism of Shh 
delivery from PNs to PWM targets, but extends this concept further by suggesting that Shh-
producing neurons can promote neurogenesis along different axes. A bi-directional signaling 
mechanism has also been proposed for Brain-derived neurotrophic factor (BDNF) in neurons 
where it is transported along neuritic processes to axons and dendrites (von Bartheld et al., 
1996). Interestingly, differential neuronal activity appears to modulate BDNF release from the 
axon and dendrite (Matsuda et al., 2009). Future studies are required to determine the mechanism 
of bi-directional Shh transport to the target fields. 
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One intriguing question raised by our study is why would PNs be charged with the complex task 
of regulating the simultaneous production of both inhibitory and excitatory interneurons? Some 
insight may be gained from the physiological function of PNs, the sole projection neurons in the 
cerebellar circuit. They integrate direct excitatory input from, in part, parallel fibers of granule 
neurons simultaneously with inhibitory input from basket and stellate cells (and Golgi cells 
indirectly), and relay cerebellar output via their projections to the DCN (Sillitoe and Joyner, 
2007). Because the balance between inhibitory and excitatory neurons is critical for modulating 
precise neuronal output from PNs, we speculate that PNs represent a sentinel population 
governing the formation of neural circuitry by synchronizing the balanced generation of 
inhibitory and excitatory interneurons. Because the cerebellum has been linked to 
neurodevelopmental disorders associated with excitatory/ inhibitory imbalance, such as the 
autism spectrum disorders (ASD), in which neuropathologies associated with PNs have been 
widely noted (Catini et al., 2008; Palmen et al., 2004; Pierce and Courchesne, 2001; Tsai et al., 
2012), this study provides an important contribution toward a greater understanding of neural 
network assembly 
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CHAPTER IV
 
 
 
ONCOGENIC SHH SIGNALING VIA GLI2 IS SUFFICIENT TO DRIVE 
FORMATION OF EWING’S SARCOMA-LIKE TUMORS INDEPENDENTLY OF 
EWS-FLI1 
 
 
 
Introduction 
 
Sarcomas represent a heterogeneous spectrum of tumors affecting numerous soft tissues, 
including muscle, fat, ligaments, and even bone. Though many sarcomas target the pediatric 
population, a few subtypes are restricted to adults (Lessnick et al., 2009). Nearly ubiquitous 
among sarcomas is the characteristic small round cell morphology, making the identification of 
other defining features necessary to discern sarcoma subtype (Fletcher et al., 2013; Lessnick et 
al., 2009). Markers of differentiation can be utilized to discriminate some sarcomas. The 
rhabdomyosarcoma (RMS) family, for example, is comprised of multiple tumor entities that 
display a spectrum of myogenic differentiation, which has led to wide spread suspicion that RMS 
originates in myogenic precursor cells (Kikuchi et al., 2011). This myogenic signature for RMS 
(determined by a Myogenin+, MyoD+, or Desmin+ status) has served as a reliable diagnostic tool 
for clinicians.  
  
However, molecular markers with such clear diagnostic power are yet to be defined for most 
other sarcoma variants, which lack a clear line of differentiation (Fletcher et al., 2013). The 
specific factors acting to drive such divergent sarcoma phenotypes are not known, but cellular 
origin and mutational profile appear to be powerful, influential forces (Kikuchi et al., 2011; 
Rubin et al., 2011). A major impediment towards developing new diagnostic markers for non-
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RMS tumors has likely been the lack of faithful, genetically inducible mouse models. In 
particular, the Ewing’s family of tumors (EFT) has been especially difficult to reproduce in mice. 
EFT includes extraosseous small round cell sarcomas (SRCS), those that affect bone, and 
peripheral neuro-ectodermal tumors (PNTs). Currently, the defining characteristic of this family 
is a chromosomal translocation at t(12;22)(q24;q12), resulting in the EWS1-FLI1 chimeric 
oncoprotein (Lessnick et al., 2009). Attempts to generate an EFT mouse model based on EWS1-
FLI1 have not been successful (Haldar et al., 2009; Lin et al., 2008; Torchia et al., 2007), and 
were likely confounded by the inherent lethality of oncogenic translocations (Haldar et al., 2007; 
Haldar et al., 2009; Straessler et al., 2013). Furthermore, even though >95% of EFT are 
associated with t(12;22)(q24;q12), the drivers of EFT sarcomagenesis downstream of the EWS1-
FLI1 oncoprotein have not been established (Lessnick et al., 2009; McAllister and Lessnick, 
2005).  
 
Several recent EFT studies have reported elevated expression of GLI1, a transcriptional activator 
of Sonic hedgehog (Shh) pathway target genes, and have described transcriptional regulation of 
GLI1 by EWS1-FLI1 (Beauchamp et al., 2009; Joo et al., 2009; Sankar et al., 2013; Zwerner et 
al., 2008). These findings are intriguing because aberrant activation of the Shh pathway by either 
deletion of the receptor, Ptch1, or activation of the signaling transducer, Smo, are sufficient to 
drive formation of RMS in numerous mouse models to date; but have not led to the formation of 
EFT (Hahn et al., 1998; Hatley et al., 2012; Mao et al., 2006; Nitzki et al., 2011; Rubin et al., 
2011). We chose to postulate whether GLI2, the primary activator of Shh target genes (Corrales 
et al., 2006), rather than GLI1, is regulated by EWS-FLI1 and if this relationship could be an 
important mechanism underlying EFT formation.  
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To test whether activated GLI2 function alone is sufficient to drive sarcomagenesis, a truncated 
human GLI2 (GLI2ΔN) that lacks an N-terminal repressor domain and thus functions as a 
constitutive activator was used. The CLEG2 allele, which encodes GLI2ΔN under control of the 
CAG promoter, has been demonstrated to function as a potent driver of basal cell carcinoma 
(Pasca di Magliano et al., 2006; Roessler et al., 2005). CLEG2 was targeted to multipotent 
mesenchymal progenitors using L7(Pcp2)-cre, and 100% of mice (termed PCG2) formed SRCS. 
PCG2 tumors were highly aggressive soft tissue sarcomas that expressed Nkx2.2, an emerging 
molecular marker for EFT and known Shh target gene (Smith et al., 2006; Vokes et al., 2007; 
Yoshida et al., 2012). Moreover, the gene expression profile of PCG2 sarcomas shows a strong 
correlation with a large cohort of human EFT samples. Enrichment of EWS-FLI1 binding in two 
~1.8 kb regions of human GLI2 suggests a direct EWS-FLI1 – GLI2 interaction may underlie 
EFT etiology. Altogether, PCG2 mice represent an EFT-like model, suggesting that Gli2 is 
sufficient to drive sarcomagenesis independent of EWS-FLI1, and that EFTs arise from the 
mesenchymal lineage. 
 
Experimental Procedures 
Animals 
All experiments were performed using young neonatal and adult animals, ages P3 – 1.5 years 
according to the NIH and VUMC Division of Animal Care. 
 
Mice of the following genetic lines, of either sex, were used: Gli1nlacZ (Bai C.B., 2002) 
L7(PCp2)-Cre (Lewis P.M., 2004), R26ReYFP (Srinivas S., 2001), Ai9 (Madisen et al., 2010), 
Pax7-creER (Murphy et al., 2011), Myf5Cre (Haldar et al., 2007), aP2-cre (Urs et al., 2006), 
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PtchlacZ (Goodrich et al., 1997), CLEG2 (Pasca di Magliano et al., 2006), and SmoM2 (Mao et al., 
2006).  
 
Tissue processing, protein isolation, immunohistochemistry, and western blotting 
Tissues were dissected out and fixed in 4% paraformaldehyde for either 4-6 hours or O/N at 4o 
C, and were either processed for frozen embedding in OCT compound or processed for paraffin 
embedding. Frozen tissues were sectioned on a Leica cryostat at 10 um, paraffin embedded 
tissues were cut at 5 um. Protein was isolated from fresh or snap-frozen tumor and tibialis 
anterior muscle using standard lysis buffer, and a BCA assay (Thermo) was used for measuring 
concentration.  
 
Antibodies  
Immunohistochemistry (IHC) and immunocytochemistry (ICC) were performed as previously 
described (Huang X. et al., 2010). The following primary antibodies were used to perform IHC 
on frozen and/ or paraffin tissue sections: chicken α-βGal (ICL), mouse α-BrdU (DSHB), mouse 
α-CyclinD1 (DSHB), mouse α-Desmin (DSHB), chicken α-GFP (Aaves), rabbit α-Gli1 (Cell 
Signaling), rabbit α-Gli2 (Gift of Jonathan EggenSchwiler, Phd, UGA), rabbit α-Ki67 
(NeoMarkers), mouse α-Laminin (Thermo), mouse α-Myc (DSHB), mouse α-Myogenin 
(DSHB), rabbit α-Myogenin (EPITOMICS), mouse α-Myf5 (DSHB), mouse α-MyoD (DSHB), 
mouse α-Nkx2.2 (DSHB), mouse α-Pax7 (DSHB), mouse α-Pax3 (DSHB), rabbit α-PDGFRα 
(Thermo), rabbit α-PPARγ (Cell Signaling), mouse α-tubulin (DSHB), mouse α-Vimentin 
(NeoMarkers). For bright-field staining, species-specific HRP-conjugated secondary antibodies 
(Invitrogen) were used followed by incubation in DAB reaction (Invitrogen). Double-labeling 
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fluorescence immunohistochemistry was performed using species-specific, AlexaFluor-tagged 
secondary antibodies Alexa 488, Alexa 568 and Alexa 647 (Invitrogen) followed by 
counterstaining with To-pro3 iodide (Invitrogen).  
 
X-gal staining and transcript detection 
X-gal staining for β-galactosidase activity was performed on post-fixed, frozen sections 
according to standard protocols. The following cDNAs were used as templates for synthesizing 
digoxygenin-labeled riboprobes: Gli1. 
 
Gene expression profiling and Statistical analyses 
RNA from tumor and unaffected tibialis muscle (n=3 animals) was isolated using a two-step 
protocol in which tissue was homogenized in Trizol and RNA was collected by phenol-
chloroform extraction and column elution with RNeasy Mini kit (Qiagen). RNA was reverse 
transcribed to create a cDNA library by the VANTAGE core at VUMC prior to paired-end 
sequencing on the Illumina platform. We first performed quality control on raw data to identify 
potential outliers before doing any advanced analysis by applying tool FastQC. RNA data 
alignment was performed by TopHat (Trapnell et al., 2009), gene quantification was done by 
Cufflinks (Trapnell et al., 2010). Unsupervised cluster analysis based on Pearson’s correlation 
coefficient on all genes shows clear separation between muscle and tumor samples. RPKM 
(reads per kilobase per million reads) based approaches with Cuffdiff (Trapnell et al., 2010) were 
used to detect differential expressed genes. False discovery rate (FDR < 0.05) was used for 
multiple test correction. 
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Microarray 
External similarity analysis was conducted using the data set GSE9103, GSE12102 (Scotlandi et 
al., 2009) and GSE37371 from Gene Expression Onmibus. GSE9103 was generated from a 
skeletal muscle transcript profiling study which contains 40 vastus lateralis muscle biopsy 
samples: 10 young sedentary, 10 older sedentary, 10 young trained, 10 older trained. GSE9103 
acted as normal samples in this analysis. Tumor counterparts were obtained from GSE12102 and 
GSE37371. GSE12102 contained 37 and GSE37371 contained 39 Ewing sarcoma samples.  
Gene expression profiling for all three datasets were conducted using Affymetrix Human 
Genome U133 Plus 2.0 Array. We downloaded the cell files and re-performed RMA 
normalization for all samples using Affymetrix’s Expression Console. 
 
Using the RMA normalized data, we performed selection normal vs. Ewing’s sarcoma gene 
expression analysis using LIMMA (Smyth, 2004) package. We compared the results from 
microarray studies and our RNAseq study and found strong similarity in term of differentially 
expressed genes. The correlation of fold change between the top 1000 differentially expressed 
genes is 0.63 with p value =2.2e-16. Such strong correlation provides strong evidence of 
similarity between the microarray and RNAseq data analysis results. Additionally, the R2 
platform was used for querying human EFT microarray datasets (Koster, 2008). Survival curves 
were generated using Prism software (GraphPad). 
 
Microscopy 
Bright-field images were collected on an Olympus BX51 upright microscope or on a Leica M165 
FC stereoscope. Detection of double-labeling was performed using either confocal imaging on a 
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Leica TCS SP5 laser-scanning or with an Olympus fluorescent microscope outfitted with an 
Optigrid system (qioptiqimaging) for optical sectioning and MetamorphTM software (Molecular 
Devices) for image acquisition. 
 
Results 
GLI2ΔN induces the formation of undifferentiated small round cell sarcoma 
Originally we sought to initiate ectopic Shh pathway activity in cerebellar Purkinje neurons by 
pairing the L7(Pcp2)-cre transgenic driver (Lewis P.M., 2004) with either SmoM2 (Mao et al., 
2006) or CLEG2 alleles (Pasca di Magliano et al., 2006). Much to our surprise, we found that 
L7(Pcp2)-cre; CLEG2 (PCG2) mice developed soft tissue tumors in the proximal limbs, head/ 
neck, and orbitals (Figure 4.1I and K). This phenotype was 100% penetrant (in both male and 
female mice) and tumors, which appeared on average around 8 weeks of life (n=46 mice), were 
highly aggressive, with potential to expand several cm within one week of first being palpable 
(Figure 4.1I and J). Basic histology indicated that PCG2 tumors exhibited the hallmark SRCS 
pathology, typified by hyper dense regions of small round cells with high nuclear to cytoplasmic 
ratio, and varying expanses of necrosis similar to human SRCS (Figure 4.1A-D). Because 
aberrant Shh pathway activity following loss of the tumor suppressor, Ptch, has previously been 
linked to the formation of RMS (Hahn et al., 1998), we utilized Ptch1+/-  (PtchlacZ) germline 
mutant mice for comparison, in which entrapped myofibers were abundant much like human 
RMS (Figure 4.1E-H). 
 
Immunophenotype indicated that PCG2 tumors consistently lacked evidence of myogenic 
differentiation, while clear reactivity for Myogenin, MyoD and Desmin was detected in Ptch1+/- 
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tumors (Figure 4.2A-F). Two other factors seen in RMS, Pax7 and PDGFRα  (Mao et al., 2006; 
Rubin et al., 2011; Taniguchi et al., 2008), were also evaluated. No Pax7 was seen in PCG2 
tumors although variable expression of PDGFRα, also a mesenchymal marker, was detected 
across a panel of several separate tumors (Figures 4.2G, H and 4.3A-J). Additionally, PCG2 
tumors often displayed a large fraction of proliferating cells, determined by Ki67 staining 
(Figure 4.3K-O), another typical feature of undifferentiated SRCS (Fletcher et al., 2013). The 
undifferentiated status of PCG2 tumors was consistent, indicated by the absence of Myogenin 
and Desmin staining (Figure 4.3P-Y). Unfortunately, we were unable to evaluate a tumor 
phenotype in L7(Pcp2)-cre; SmoM2 animals because these mice succumbed at weaning from 
brain malformations and concomitant low birth weight (Figure 4.4A-B’).  
 
Further analysis of PCG2 tumors indicated persistent Shh pathway activity, indicated by Gli1 
mRNA, and Gli1 and Cyclin D1 protein, direct read-outs for Shh signaling (Figure 4.5A-B, D) 
(Bai C.B., 2002; Kenney and Rowitch, 2000). We found that PCG2 tumors display a high 
frequency of primary cilia (Figure 4.5E, F). Additionally, Gli2 protein was distributed widely in 
PCG2 tumors, though localization appeared to be largely cytoplasmic, not compartmentalized at 
the distal tip of cilia as reported in other contexts (Figure 4.5E,’ F’) (Qin et al., 2011). Gli2 was 
not detectable in Ptch1+/- RMS tumors (Figure 4.5C), suggesting that the level of Shh pathway 
activity may be another distinction between these two SRCS phenotypes. Altogether, these 
findings indicate that oncogenic Gli2 function is sufficient to drive the formation of 
undifferentiated, soft tissue SRCS distinctly different from RMS.  
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Figure 4.1. GLI2Δ N induces the formation of undifferentiated small round cell sarcoma in 
mice.  
(A-H) Basic histological profile of PCG2 tumors (A, C) compared to human USTS (B, D), 
Ptch+/- RMS (E, G), and human RMS (F, H). (I) External view of PCG2 tumor mass located on 
the right proximal hind limb. (K) Kaplan-Myer survival plot for PCG2 mice. Scale bars indicate 
50 µm.   
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Figure 4.2. Immunophenotype indicates tumors from PCG2 mice are undifferentiated 
SRCS.  
Immunohistochemical profile of tumors from PCG2 (A, C, E, G) and Ptch+/- mice  (B, D, F, H). 
PCG2 tumors lack myogenic marker expression, while Ptch+/- RMS display robust expression for 
Myogenin (A versus B), MyoD (C versus D), Desmin (E versus F), and Pax7 (G versus H). Scale 
bars indicate 50 µm.   
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Figure 4.3. Immunophenotype of PCG2 SRCS does not vary significantly across many 
samples.   
(A-Y) Immunohistochemical profile indicates that phenotype of PCG2 mice is not variable. 
PCG2 tumors consistently lack expression of RMS markers Pax7 (A-E), PDGFRα (F-J), 
Myogenin (P-T), and Desmin (U-Y), but typically display a large proliferative fraction marked 
by Ki67 expression (K-O). Scale bars indicate 50 µm.   
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Figure 4.4. L7(Pcp2)-cre; SmoM2 succumb prior to tumor formation due to brain 
malformation. 
(A-B’) External views of the dorsal surface of SmoM2 (A, A’) and L7(Pcp2)-cre; SmoM2 (B, B’) 
adult brains. Forebrain (white outline) of L7(Pcp2)-cre; SmoM2 cerebella (B, B’) exhibited large 
bulges that protruded through the skull, and cerebella (red outline) were malformed, with 
extreme narrowing along the medial-lateral axis when compared to SmoM2 brains (A, A’). Cb, 
cerebellum; Fb, forebrain; Mb, midbrain. 
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Figure 4.5. Persistent Shh pathway activity was detected in PCG2 SRCS. 
(A-F’) Evaluation of Shh pathway activity in PCG2 tumors, measured by Gli1 mRNA (A, A’) 
and Gli2 staining (B), which was not detectable in Ptch+/- RMS (C). Gli1 expression was robust 
in regions of tumor (black outline), but was not detectable in adjacent skeletal muscle fibers 
depicted on the left (A). (D) Western blotting further confirmed activation of pathway activity, 
indicating robust levels of Shh targets Gli1 and Cyclin D1, while Myc and β-actin served as 
controls. (E-F’) Staining for Arl13b (green), indicated that PCG2 tumors are widely ciliated and 
that Gli2 protein (red), is only detected in cytoplasmic pools, not in cilia distal tips. Scale bars 
indicate 50 µm (A-C) and 25 µm (E-F’). 
 
 
Gene profiling of PCG2 tumors highlights the Ewing’s family of tumors 
In order to isolate a more specific SRCS subtype designation for PCG2 tumors, we evaluated 
their gene expression profile using Next-Gen RNAseq. Unbiased and hierarchal clustering 
revealed a distinct signature for tumor versus unaffected control tissue (tibialis anterior muscle) 
(Figure 4.6A). Among the top 100 differentially expressed genes we found cell cycle genes, 
numerous mesenchymal progenitor genes, and several Shh target genes, the most intriguing of 
which was Nkx2.2 (Figure 4.6B). Mounting evidence has indicated expression of this pro-neural 
transcription factor is tightly correlated with the Ewing’s family of tumors (EFT), but not other 
SRCS subtypes (Smith et al., 2006; Yoshida et al., 2012).  
 
Indeed, the immunophenotype of PCG2 tumors included robust expression of Nkx2.2, while 
Ptch+/- RMS was clearly negative (Figure 4.6C, D). We obtained numerous human EFT 
specimens from archives at VUMC (n=13), which further corroborated this trend (Figure 4.6E, 
F). We then compared the top 1000 differentially expressed genes from our PCG2 profile with 
an additional human EFT microarray dataset (n=37), and found a Pearson’s correlation value of 
0.65, indicating strong similarity between these two genes profiles (a value of 1 indicates an 
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exact match). We queried an additional gene expression dataset using the R2 platform (Koster, 
2008), representing a broad spectrum of human EFT specimens (n=154 combined), and 
independently found a consistent association of NKX2.2 expression and EFT (Figure 4.7A).  
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Figure 4.6. Gene profiling of PCG2 tumors highlights the Ewing’s family of tumors. 
(A) Clustering analysis showing 100 most differentially expressed genes from PCG2 tumor 
versus unaffected, adjacent tibialis anterior muscle (n=3) from RNA-seq expression profiling. 
(B) Expression of relevant pathway components ranked by clustering and gene ontology 
comparison. PCG2 tumors showed high expression of Shh pathway target genes, mesenchymal 
genes, and EFT markers, Nkx2.2 and CD99, but did not strongly express adipogenic or 
myogenic markers. (C-F) Immunophenotyping indicated that PCG2 tumors robustly expressed 
EFT marker, Nkx2.2 (C), which was not detectable in Ptch+/- RMS (D). Strong NKX2.2 
expression was similarly seen in human EFT samples (E) that showed similar SRCS morphology 
to PCG2 tumors at the basic histopathology level (F).  
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This difference between PCG2 and human EFT gene profiles may be explained, at least in part, 
by differences between target gene activation by the EWS-FLI1 oncoprotein versus GLI2 alone, 
which itself may be an EWS-FLI1 transcriptional target. In pursuit of this latter notion, we again 
queried the above human EFT specimens (n=154 combined) using the R2 platform (Koster, 
2008), and found high GLI2 and PTCH1 expression was frequently associated with this sarcoma 
family (Figure 4.7B, C). We speculated that if EWS-FLI1 mediates transformation by utilizing 
GLI2, an EWS-FLI1 – GLI2 interaction should be detectable. ChIP-Seq using an HA-tagged 
EWS-FLI1 was previously reported (Patel et al., 2012), and we queried these data and mapped 
two EWS-FLI binding peaks to GLI2 on chromosome 2. One peak corresponded to a 1.7 kb 
region with 13 potential FLI1 binding motifs, and a second mapped to a 1.7 kb region with 8 
motifs (Figure 4.7D and not shown). These data strongly suggest that EWS-FLI1 binds GLI2, 
but additional work is required to fully demonstrate not only that this interaction occurs, but also 
that it regulates transcription of GLI2 and confers tumor propagating potential to human EFT 
cells. For a detailed list of experiments, refer to CHAPTER V, pages 119-129.  
 
PCG2 tumors originate in multipotent mesenchymal progenitors  
Determinations regarding the cellular origin for most sarcoma variants largely remain open-
ended, owing to their undifferentiated phenotype. A clear line of differentiation, as seen in RMS, 
is not available to provide insight into their lineage. For EFT cellular origin, two schools of 
thought currently posit that EFT arise either from mesenchymal stem cells, or from the neural 
crest (Jedlicka, 2010). To investigate the cellular origin of PCG2 tumors, L7(Pcp2)-cre mice 
were employed for fate-mapping studies. In addition to reported expression in Purkinje neurons 
(Lewis P.M., 2004), cre recombinase activity was detected in forelimb level dermamyotome cells 
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expressing either Pax3, Pax7, Myf5 or Myogenin in L7(Pcp2)-cre; RosaeYFP embryos between 
e9.5-e11.5 (Figure 4.8A-D). This molecular signature is indicative of mesenchymal progenitor 
cells, collectively known to generate skeletal muscle, dermis, adipocytes, bone, and satellite cells 
(Sabourin and Rudnicki, 2000). Consistent with this labeling, at e16.5-e17.5 reporter+ cells were 
found in dorsal and ventral myofibers of the trunk, but not limbs, in the proximal-most humorous 
bone primordium, and within the interstitium (Figure 4.9A-C’).  
 
In distal hind limb muscles (tibialis anterior and gastrocnemius) from L7(Pcp2)-cre; Ai9 mice at 
P3, I found only that interstitial, myofiber-associated (MFA) cells expressing Vimentin were 
reporter+, but myofibers themselves were not (Figure 4.9D, D’). Imaging of intact musculature 
in L7(Pcp2)-cre; Ai9 mice at P30 clearly indicated that myofibers of the head/ neck and 
proximal limbs were indeed reporter+ (Figure 4.10A-B’). The identity of these cells was clearer 
in cross sectional images of proximal hind limb in which myofibers were tdTomato+, as were 
PPARγ+ adipocytes, consistent with embryonic fate-mapping (Figure 4.10C, C’). Allocation of 
the L7(Pcp2)-cre lineage did not appear to be altered by aberrant Shh signaling, since labeling in 
cross sections of PCG2; Ai9 limbs was comparable to that seen in PCG2 mice (not shown). 
Altogether, these data confirm that the L7(Pcp2)-cre lineage encompasses multipotent 
mesenchymal progenitors.  
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Figure 4.7. Expression of GLI2 in human EFT is likely driven by EWS-FLI1 activation. 
(A-C) Expression of NKX2.2 and Shh pathway genes GLI2 and PTCH1 in a cohort of human 
EFT samples (n=37 and n=117) versus normal skeletal muscle. LOG2 expression displayed 
using the R2 microarray analysis and presentation platform. (D) Mapping of enrichment peaks 
for HA-EWS-FLI1 at three distinct locations on the GLI2 sequence using UCSC software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. The Pcp2 lineage includes mesenchymal progenitors in the dermamyotome.  
(A-D) Transverse sections of L7(Pcp2)-cre; R26ReYFP embryos (e11.5) at the forelimb level 
depicting the transient dermamyotome (white outline, A and C). Pcp2 lineage cells (red) express 
mesenchymal progenitor markers Pax7 (A, A’), Pax3 (B), Myogenin (C, C’), and Myf5 (D). 
Scale bars represent the indicated distances. 
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Figure 4.9. Late embryonic trunk muscle, bone and interstitial cells emerge from Pcp2 
lineage cells. 
(A-C’) Transverse sections of L7(Pcp2)-cre; Ai9 embryos (e16.5-e17.5) at the forelimb level 
depicting Pcp2 lineage cells (red) within the dorsal skeletal musculature, expressing laminin (A, 
A’), as well as within the proximal humorous bone (B) and the interstitium (B-B”). A subset of 
interstitial cell expressed mesenchymal marker Vimentin (C, C’). (D, D’) Cross sections of 
L7(Pcp2)-cre; Ai9 tibialis anterior muscle indicated that Pcp2 lineage cells (red) were exclusively 
part of the interstitial space between laminin+ myofibers at P3. Lam, Laminin. Scale bars indicate 
25 µm unless otherwise indicated. 
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Figure 4.10. The Pcp2 lineage contributes extensively to skeletal musculature and fat.  
(A-B’) whole mount fate-mapping of adult L7(Pcp2)-cre; Ai9 mice. Direct fluorescence for 
tdTomato indicated that Pcp2 lineage cells (red) contribute widely to skeletal musculature (blue 
outline). (C, C’) Cross sections of proximal hind limb revealed that Pcp2 lineage cells generate 
both mature myofibers (C) and PPARγ+ adipocytes (C’). White arrowheads indicate double 
labeled cells. Scale bars indicate 25 µm unless otherwise indicated.  
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Lineage-specific activation of GLI2ΔN phenocopies EFT-like SRCS  
Having prospectively traced back the origin of PCG2 tumors, we wanted to narrow down 
whether tumor-propagating potential resides within lineage-committed precursors versus 
multipotent mesenchymal progenitors. To this end GLI2ΔN was selectively activated in three 
distinct lineages: (1) early myoblasts, satellite cells and precursors of embryonic brown fat using 
Myf5Cre mice (Beauchamp et al., 2000; Cornelison and Wold, 1997; Kuang et al., 2007; Seale et 
al., 2008), (2) adipocyte precursors using aP2-cre mice (Hatley et al., 2012; Urs et al., 2006), and 
postnatal and adult satellite cells using Pax7-creER mice (Murphy et al., 2011). 
  
Targeting GLI2ΔN to Myf5Cre cells drove tumor formation in ~50% of the resulting M5G2 mice 
(n=11). These animals exhibited highly aggressive EFT-like SRCS typically by four weeks of 
age (Figure 4.11A, I), usually near the head and proximal fore limbs. The remainder of M5G2 
mice were severely runted and succumbed prior to tumor formation. Interestingly, M5G2 tumors 
were histopathologically indistinguishable from PCG2; no detectable expression of Myogenin, 
MyoD, Desmin or Pax7 could be found, although robust Nkx2.2 expression was consistently 
observed in all M5G2 tumors that I evaluated (Figure 4.11B-D).  
 
Though Myf5Cre cells are primarily myogenic precursors, the inclusion of fat and satellite cells in 
this lineage, albeit minor, prompted us to further evaluate tumor origin. Activation of GLI2ΔN in 
fatty acid binding protein-4 (fabp4)/ adipocyte protein-2 (aP2)+ precursors of both brown and 
white fat using aP2-cre mice resulted in a SRCS phenotypic outcome similar to PCG2 and 
M5G2 mice (Figure 4.7E). 100% of aP2G2 animals formed tumors in similar regions, including 
the head, neck, orbitals, and proximal limbs within 8 weeks on average (Figure 4.11J). 
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Occasionally tumors also occurred in the genitourinary region, likely owing to an accumulation 
of adipocytes in this anatomical site (see below). Immunophenotyping indicated that aP2G2 
tumors were histopathologically indistinguishable from PCG2 and M5G2 mice (Figure 4.11F-
H).  
 
Though these findings seemed to help narrow down the EFT cellular origin to adipocyte 
precursors, further evaluation of the aP2-cre lineage using aP2-cre; Ai9 mice surprisingly 
revealed some contribution of these cells to myofibers (Figure 4.12C’, E, E’). This finding 
contrasts what is known regarding the contribution of fabp-4/ aP2+ cells (Hatley et al., 2012), but 
is the only global assessment of this lineage to the intact organism. Together, these findings 
indicate that GLI2ΔN tumor-initiating potential is not likely restricted to either myogenic or 
adipogenic precursors, or their precursors. 
 
One additional cellular lineage that I chose to evaluate was myogenic satellite cells, which 
persist in the adult skeletal musculature (Kuang et al., 2007). GLI2ΔN was activated in Pax7+ 
satellite cells using Pax7-creER mice, which received tamoxifen (TM) on P3 or P60. Regardless 
of when GLI2ΔN activation was induced, all P7G2 mice to date formed SRCS, between 3-10 
weeks of life (Figure 4.13K, n=6). Largely, tumors affected proximal limb and face regions, 
however, in some instances P7G2 mice also developed tumor foci along the trunk, which 
appeared to emerge from muscle associated with the lumbar vertebrae (Figure 4.13B). Though 
metastases are known to occur in EFT (Shukla et al., 2013), it is difficult to conclude whether 
these foci were primary tumors or metastatic tumors.  
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Figure 4.11. Lineage-specific activation of GLI2Δ N phenocopies EFT-like SRCS.  
(A-H) Basic histopathology and immunophenotyping of M5G2 (A-D) and aP2G2 (E-H) mice 
indicated that activation of GLI2ΔN in either lineage recapitulates the EFT-like SRCS phenotype 
of PCG2 mice. No expression of myogenic markers Myogenin (B, F) or Desmin (C, G) was 
detectable, although robust expression of Nkx2.2 was observed (D, H).  (I, J) Kaplan-Myer 
survival curves for M5G2 (I) and aP2G2 (J) mice. Scale bars indicate 50 µm. 
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Figure 4.12. The aP2 lineage makes an unexpected contribution to skeletal muscle.  
(A-D’) whole mount fate-mapping of adult aP2-cre; Ai9 mice. Direct fluorescence for tdTomato 
indicated that aP2 lineage cells (red) contribute widely to fat stores throughout the animal. (C, 
C’) Cross sections of proximal hind limb revealed that aP2 lineage cells also contribute to 
mature, Laminin+ myofibers (E, E’). Scale bars represent the indicated distance.  
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Figure 4.13. Postnatal Pax7+ cells can be transformed by GLI2Δ N to form EFT-like SRCS. 
(A-J) Basic histopathology and immunophenotyping of P7G2 mice indicated that activation of 
GLI2ΔN in postnatal Pax7+ cells recapitulates the EFT-like SRCS phenotype of PCG2, M5G2, 
and aP2G2 mice (A). (A-B”) Histopathology revealed several attributes unique to P7G2 mice; 
cystic spaces filled with eosinphilic matrix (A), rare spinal tumor foci (B), which displayed large 
areas of osteoid-like matrix (B’) and entrapped muscle fibers (B”). Expression of myogenic 
markers Myogenin (C, D), MyoD (E, F) and Desmin (G, H) was detectable only in limited 
regions, most likely a result of tumor-induced myopathy in adjacent skeletal muscle. Robust 
expression of Nkx2.2 was consistently observed (I, J).  (K) Kaplan-Myer survival curve for 
P7G2 mice. Scale bars indicate 50 µm. 
 
 
Additionally, P7G2 tumors frequently exhibited histopathological features not seen in PCG2, 
M5G2, or aP2G2 tumors. The most obvious were vast cystic spaces filled with eosinphilic 
deposits, some of which resembled osteoid, a defining feature of osteosarcoma (Figure 4.13A, 
B’). The second feature was a combination of extensive infiltrating Desmin+ myofibers (Figure 
4.13B”, H) and regions of Myogenin+ or MyoD+ cells, which may be evidence of tumor-induced 
myopathy (Figure 4.13D, F). Though these histopathological features were intriguing, they were 
not sufficient to change the undifferentiated SRCS designation, since P7G2 tumors were 
otherwise immuno-histopathologically similar to PCG2, M5G2, and aP2G2 tumors (Figure 
4.13C, E, G, I). Collectively, these analyses highlight two sources of EFT initiating cells, either 
multipotent Pax7+ cells disseminating from the embryonic dermamyotome or those embedded in 
the postnatal skeletal muscle interstitium. 
 
Attenuating Shh pathway function modifies SRCS phenotype 
The initial finding that GLI2ΔN is sufficient to induce EFT-like SRCS is intriguing, considering 
that activation of Shh signaling at the level of Patch/ Smo leads to RMS. Such divergent 
phenotypic outcomes may indicate that the intensity of pathway activation is a key influential 
	   94	  
force in the sarcoma spectrum. To test this notion, one copy of Gli1, the other transcriptional 
activator of Shh target genes, was removed in an attempt to attenuate pathway activity. Only 
30% of the resulting PCG2; Gli1nlacZ mice developed tumors with an average onset of 6 months, 
while the remaining 70% succumbed to old age between 1.5-2 years (Figure 4.14M). 
Histopathological analyses revealed distinctive morphological features not seen in any PCG2 
tumors, including dense cell clusters surrounded by rich collagen deposits or very large, fluid-
filled cystic spaces (Figure 4.14B, D, and not shown). Importantly, in addition to these 
distinguishing features, the immunophenotype of PCG2; Gli1nlacZ tumors did differ significantly 
from PCG2 tumors; expression of Nkx2.2 was not detected, though neither were myogenic RMS 
markers (Figure 4.14F, I, J). PCG2; Gli1nlacZ tumors, similar to PCG2, were highly proliferative 
and exhibited persistent Shh pathway activation (Figure 4.14G, H, K, L). However, the 
meaningful differences described above indicate that attenuation of pathway activity can 
substantially modify the phenotypic outcome of SRCS, reverting an EFT-like phenotype to 
undifferentiated SRCS.  
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Figure 4.14. Attenuation of Shh signaling activity modifies the SRCS phenotype. 
(A-M) Comparison of tumors from PCG2 (A, C, E, G) and PCG2; Gli1+/- (B, D, F, H) mice 
indicated that attenuation of Shh pathway activation modifies SRCS phenotype. (A-D) Basic 
histopathology indicated that PCG2; Gli1+/- tumors exhibited dense cellular clustering and rich 
collagen deposits (blue) not seen in PCG2 tumors. Most notably, no expression of Nkx2.2 was 
detected in PCG2; Gli1+/- tumors (F versus E).  However, both tumors exhibited dense 
proliferative fractions, indicated by Ki67 staining (G, H). The differentiation status of PCG2; 
Gli1+/- tumors was not changed; no expression of either Myogenin (I) or Desmin (J) was 
detected. Persistent Shh pathway activity was evident, indicated by staining for Gli2 (K) and X-
gal (L). (M) Kaplan-Myer survival curves for PCG2 and PCG2; Gli1+/- (J) mice. Scale bars 
indicate 50 µm. 
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Figure 4.15. The level of Shh pathway activation determines SRCS phenotypic outcome. 
(1) A schematic diagram summarizing the fate of several mesenchymal precursor populations 
based on fate-mapping studies described in this thesis work and by others. Briefly, Pcp2-cre cells 
at mid-embryogenesis generate myogenic (Pax7/3+, Myf5+, Myogenin+) and adipogenic (Fabp4/ 
aP2+) precursors, as well as postnatal satellite cells (Pax7+).  (2) A summary depicting the 
prospective Rhabdomyosarcoma cellular origin with respect to Shh pathway activation using 
either deletion of Ptch1 in uncommitted precursor cells or SmoM2 in the adipogenic lineage. (3) 
A summary of the work described here; deregulated Shh signaling using activation GLI2ΔN in 
Pcp2-cre, Myf5Cre, aP2-cre, and Pax7-creER lineage cells results in EFT-like SRCS. 
Surprisingly, fate-mapping studies with aP2-cre mice indicated this lineage also contributes to a 
subset of skeletal myofibers. (4) Attenuation of Shh pathway activation by deletion of one Gli1 
allele from PCG2 mice modified the tumor outcome from an EFT-like phenotype to 
undifferentiated SRCS, for which no molecular diagnostic markers are currently available. 
 
 
Discussion 
Collectively, the studies described here extend the connection between deregulated Shh pathway 
activity and cancer, providing a previously unappreciated link to the formation of EFT-like 
SRCS. Our data clearly show that elevated GLI2 function is sufficient to potently mediate EFT 
sarcomagenesis, independently of the characteristic EWS-FLI1 oncoprotein. However, our work 
also suggests that GLI2 is a key mediator acting directly downstream of EWS-FLI1, which 
would not be dispensable in the human tumor context. PCG2 mice are the first genetically-
inducible model for EFT, providing a more complete understanding of specific molecular events 
that drive EFT formation and new insight regarding the cellular origin of Ewing’s sarcoma, 
linking it to multipotent mesenchymal progenitors and satellite stem cells. 
 
An EWS-FLI1 – GLI2 interaction likely underlies EFT formation 
Previous studies have implicated the GLI family of proteins as oncogenes; in particular GLI2 is 
known to be upregulated in numerous human cancers, including glioma (Ruiz i Altaba et al., 
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2002). The full-length human GLI2 sequence was found to encode an 328 amino acid N-terminal 
domain that imposes strong repressor function, and the truncated GLI2ΔN mutant isoform can 
act as a potent oncoprotein when expressed in mice (Pasca di Magliano et al., 2006; Roessler et 
al., 2005). It is unlikely that truncating mutations in GLI2 will be linked to the etiology of EFT, 
since no studies to date have implicated such mutations in any human cancer, rather GLI2 over-
expression mediated by unknown means has been found. Rather, our data suggest that activation 
of GLI2 expression occurs through direct binding of EWS-FLI1 at two distinct locations in the 
GLI2 sequence.  
 
The EWS-FLI1 translocation is found in the vast majority of EFT cases and appears to be the 
major driver of sarcomagenesis. It is difficult, therefore, to understand why past attempts to 
produce a genetically-inducible EFT mouse using EWS-FLI1 have not succeeded. Targeting of a 
R26R-driven EWS-FLI1 to hematopoietic tissues caused rapid onset of myeloid/ erythroid 
leukemia (Torchia et al., 2007), while activation of a CAG-driven EWS-FLI1 in mesenchymal 
cells led to abnormal limb development and accelerated formation of osteosarcoma in a p53-/- 
background (Lin et al., 2008). Activation of Shh signaling could be required to prime cells for 
transformation or to better tolerate EWS-FLI1. To test this, introduction of full-length human 
GLI2 together with EWS-FLI1 into the mesenchymal lineage, or alternatively, introduction of 
EWS-FLI1 into the Ptch+/- background could be used in an attempt to induce EFT formation. 
Modeling EFT with an autonomously activated GLI2 allowed us to bypass inherent difficulties 
associated with EWS-FLI1, but the potential requirement for EWS-FLI1 – mediated GLI2 
activation underscores the importance of PCG2 mice as an accurate recapitulation of EFT. 
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Cell of origin and mutational profile shape sarcoma phenotypic outcome 
Even though mouse modeling difficulties have thus far prevented researchers from gaining new 
understanding of EFT, extensive efforts have been made to model other sarcoma variants and 
ascertain their respective cellular origins, including multiple RMS entities, clear cell sarcoma and 
synovial sarcoma (Haldar et al., 2007; Haldar et al., 2009; Keller et al., 2004; Straessler et al., 
2013). Many studies have utilized activation of the Shh pathway to induce embryonal RMS 
(eRMS), which indicate the cellular origin could either be uncommitted, embryonic precursors or 
adipocyte-committed precursors (Hahn et al., 1998; Hatley et al., 2012; Mao et al., 2006; Nitzki 
et al., 2011). Yet, others have incorporated compound mutational profiles (including Ptch 
deletion) into a wide range of cellular lineages, ultimately describing a tumor continuum that 
connects RMS to undifferentiated pleomorphic sarcoma (Rubin et al., 2011). Our work, 
however, may have illuminated a much broader sarcoma spectrum, providing an unappreciated 
link between RMS and EFT. 
 
Based on our findings, EFT-like undifferentiated SRCS can arise from lineage-restricted Myf5+, 
aP2+, or postnatal Pax7+ cells. Even though cell of origin contributes to outcome, mutational 
profile may be the principal driver dictating tumor phenotype. For instance, activation of Shh 
signaling in the Myf5Cre lineage using Ptch deletion induces RMS in <5% of mice (Nitzki et al., 
2011), while activation with SmoM2 is embryonic lethal (Hatley et al., 2012). Elsewhere, 
Myf5Cre; p53-/-; Ptch+/- mice were reported to develop multiple sarcoma types, including RMS, 
pleomorphic sarcoma and osteosarcoma, similar to postnatal activation of Shh signaling in Pax7-
creER; p53-/-; Ptch+/- mice (Rubin et al., 2011). Interestingly, Ptch deletion in these studies acted 
as a strong modifier of tumor phenotype, favoring myogenic differentiation over undifferentiated 
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entities mostly seen in Myf5Cre; p53-/- and Pax7-creER; p53-/- mice (Rubin et al., 2011). No doubt, 
the level at which Shh pathway activation occurs is a critical determinant of outcome, but 
mechanisms driving such divergent phenotypes are not clear. 
 
Reaching different thresholds of pathway activation may invoke distinctive modes of action for 
downstream mediators. We know that in the developing embryo, induction of Myf5 expression 
by Shh is required for epaxial muscle specification (Gustafsson et al., 2002). Since the 
expression of the primary myogenic regulatory factors (MRFs), Myf5 and MyoD, is required for 
production of Myogenin+ myoblasts (Sabourin and Rudnicki, 2000), which are a hallmark of 
RMS, it seems fitting that aberrant Shh pathway activity in precursors of muscle can drive the 
formation of myogenic RMS.   
 
However, it is counterintuitive that the same oncogenic force could also drive the formation of an 
undifferentiated SRCS, like EFT. A possible explanation underlying this finding could be that 
higher level pathway activity mediated by GLI2ΔN could activate Nkx2.2, which is currently the 
most reliable molecular marker for EFT and is itself an important mediator of sarcomagenesis 
(Smith et al., 2006; Yoshida et al., 2012). Indeed, Nkx2.2 is a known Shh transcriptional target in 
the ventral neural tube (Vokes et al., 2007) where Shh dosage is the strongest and Gli2 primarily 
mediates target gene expression (Cho et al., 2008; Eggenschwiler et al., 2006; Matise et al., 
1998). Induction of ectopic Nkx2.2 by GLI2 could be a critical step towards promoting an EFT-
like phenotype. Furthermore, the absence of Nkx2.2 expression in RMS may stem from an 
insufficient level of Shh pathway activation. An additional possibility is direct repression of 
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myogenic differentiation by Gli-mediated blockade of MRF activation, since Gli1/ Gli2 have 
been shown elsewhere to block transcriptional activity of Myf5 and MyoD (Gerber et al., 2007).  
 
PCG2 SRCS are distinct from other Shh-driven tumors 
Other studies have compared SmoM2 and CLEG2 alleles to investigate aberrant Shh pathway 
activity in medulloblastoma and basal cell carcinoma (Han et al., 2009; SY et al., 2009). In both 
cases, when SmoM2 was used the resulting tumors were widely ciliated, similar to PCG2 EFT-
like SRCS. However, it was found that the primary cilium potently represses GLI2ΔN function; 
only in the absence of primary cilia could GLI2ΔN fully promote medulloblastoma or basal cell 
carcinoma formation. Thus it is surprising that GLI2ΔN mediates such potency despite the 
ciliated status of PCG2 tumors. It is important to note that human EFT specimens are ciliated 
(not shown). However, this conundrum begs the question, could PCG2 tumor phenotype be 
modified in the absence of primary cilia beyond potential changes in aggressiveness? This query 
could easily be resolved by ablating primary cilia with conditional deletion of either Kif3a or 
IFT88 floxed alleles. However, this repressive effect may be cell type-dependent, explaining 
why Purkinje neuron defects were not apparent in PCG2 animals.  
 
CLEG2 has also been used to model pancreatic carcinoma, and when activated in the pancreatic 
epithelium induces neoplasia, categorized as undifferentiated carcinoma lacking any character of 
differentiated pancreatic cells types. However, only when combined with an activating Kras 
mutation (KrasG12D) was CLEG2 able to recapitulate the earliest stages of pancreatic ductal 
adenocarcinoma (PDA) (Pasca di Magliano et al., 2006). Elsewhere, studies using SmoM2 
targeted to the pancreatic epithelium found this oncogene was not able to induce neoplasia, 
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providing an additional example that the level of Shh pathway activation can mediate very 
different tumor outcomes (Tian et al., 2009). Hopefully, our studies will open up important new 
territory for cancer researchers. Altogether our work identified GLI2 as a key mediator of EFT 
sarcomagenesis acting downstream of EWS-FLI1, highlighting GLI2 as a potential therapeutic 
target in EFT. Thus our mouse models offer a variety of powerful systems in which to evaluate 
EFT-targeted therapeutic agents. 
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CHAPTER V
 
FUTURE DIRECTIONS 
 
A useful measurement that weighs the relative impact of a study is to determine how many 
subsequent studies and findings to which it ultimately leads. The two projects I described in 
CHAPTERS III to IV will hopefully lead to many more interesting and important discoveries. 
Here, I will attempt to outline the next steps I would take to follow up these studies and where I 
anticipate their respective trajectories leading.  
 
In CHAPTER II, I described a population of Shh-responding, proliferative GABAergic precursors 
in the cerebellar PWM niche that express transcription factor Ptf1a (Figure 3.1H’, I). 
Previously, Ptf1a function in the developing CNS has been linked only to fate specification, and 
Ptf1a+ cells were thought to be exclusively post-mitotic (Hoshino et al., 2005; Pascual et al., 
2007). My findings revealed an important mechanism supporting the rapid accumulation of 
GABAergic precursor cells in the PWM, driven by Ptf1a+ transient amplifying cells. Although 
these precursors respond to Shh, we cannot be entirely certain that this signal functions to induce 
proliferation. Although I ablated Shh reception in the parent progenitor population using TncYFP-
CreER mice and subsequently found a near complete loss of Ptf1a+ precursors (Figure 3.9E, F, N), 
I never directly removed Shh reception in Ptf1a+ cells. Therefore, it would be fascinating to 
delete Smo using Ptf1aCre or Ptf1aCreER mice to determine whether Shh acts as a proliferative 
signal or if it plays an additional role, such as in lineage or fate specification.  
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I would incorporate a reporter strain, such as RosaeYFP, to track descendants of recombined Ptf1a+ 
parent cells. Most likely, I would find a reduction in the proliferative capacity of the latter 
population, causing a reduction in ML GABAergic inhibitory interneurons that I have found to 
descend from them (Figure 3.2C). This outcome may cause a general loss of both ML 
interneuron subtypes (basket and stellate cells), or may be skewed towards a preferential loss of 
stellate cells, the later born subtype. Another possible outcome could be a fate change in Ptf1a+, 
SmoF/- mutant cells in which they revert to a glial precursor-like cell. I reported that GABAergic 
interneurons are co-generated in the PWM alongside astrocytes (Figure 3.3H, I), so it would be 
interesting to learn that Shh signaling also functions in Ptf1a+ cells to maintain them on the path 
to neuronal fate.  
    
A more complete time-course to elaborate on when Ptf1a+ cells divide in the PWM is key for 
understanding Shh function. Even though I demonstrated that Shh-responding cells divide in the 
PWM at P3 and P5, they represent multiple subpopulations; including CD133+ multi-potent 
primary progenitors, Ptf1a+ transient amplifying cells and CD15+ astrocyte intermediate 
progenitors (Figure 3.14G). It is unclear when or if Shh-responding, Ptf1a+ cells divide. 
Additionally, Shh signaling appears to be undetectable by P6 when I found that a fraction of 
Ptf1a+ cells in general are dividing. Therefore, room for anticipating multiple possible outcomes 
exists, all of which are exciting to consider. Shh signaling might initiate and maintain the 
majority of cellular divisions occurring in the Ptf1a+ population, but it may also, or alternatively, 
specify GABAergic fate by inducing the expression of pro-neural transcription factors like Ptf1a 
itself. Certainly, many important details and functions remain to be described. 
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Even though the exact function of Shh signaling in Ptf1a+ cells is uncertain, ablating this 
signaling relationship would be expected to somehow disrupt the integration of ML inhibitory 
interneurons into the cerebellar circuit. These cells maintain connectivity with PNs, the sole 
projection neuron in the cerebellum, and provide inhibitory feedback, thus playing an important 
role in balancing excitatory/ inhibitory signaling (Sillitoe and Joyner, 2007). Shh plays an 
important part in orchestrating the formation of a completely wired and balanced neuronal 
network (Fleming et al., 2013). Because imbalances in excitatory/ inhibitory signaling are a 
hallmark feature of neuropsychiatric disorders, including autism, we could extend our studies to 
include evaluating whether PN activity is altered in our genetic mutant system using 
electrophysiology (Ramamoorthi and Lin, 2011).  
 
Indeed, early collaborative work with the Danny Winder laboratory at VUMC has allowed us to 
successfully perform attached whole cell patched clamping of PNs to record spontaneous 
inhibitory postsynaptic currents (IPSCs). The use of Ptf1a-driven deletion of Smo is highly 
amenable to such studies because overall cerebellar cortical architecture would likely be intact, 
unlike the TncYFP-CreER; SmoF/- mutants I described in CHAPTER III, which display some cerebellar 
hypoplasia and cortical layering defects. The analyses I am proposing here could be combined 
with neuro-behavioral assays to more firmly link Shh function, and the PN, to the origin of 
neurodevelopmental disorders like autism.  
 
In addition to the relationship between Ptf1a+ cells and Shh that I found in the PWM, two other 
Shh-responding populations I described there are TncYFP-low, CD133+ primary progenitors and 
TncYFP-low, CD15+ astrocyte precursors (Figure 3.14G). Further evaluation of these cells and their 
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specific requirements for Shh is warranted. I refer to TncYFP-low, CD133+ cells as primary 
progenitors because they appear to be multi-potent, stem cell-like parent cells generating both 
Ptf1a+ and TncYFP-low, CD15+ cell types. Similar to Ptf1a+ cells, I found that CD15+ cells are 
largely absent in the PWM of TncYFP-CreER; SmoF/- mutants (Figure 3.11B, D). It is difficult to say 
exactly why this occurs. The easy explanation would be that TncYFP-low, CD15+ cells require Shh 
to provide a mitogenic signal, inducing their proliferation and expansion of the CD15+ astrocyte 
progenitor pool. Alternatively, however, these cells may prematurely differentiate, and a similar 
conundrum also exists for TncYFP-low, CD133+ cells following Smo ablation. These cells could 
either fail to sufficiently divide and propagate downstream progenitor subpopulations or they 
could perhaps lose their stem cell identity and prematurely differentiate. Based on my 
characterization of TncYFP-CreER; SmoF/- mutants so far it is hard to say which scenario is the right 
one, although I am confident that loss of viability is not a major factor for any of the above 
populations based on my findings in CHAPTER III. 
 
Though somewhat challenging, an elegant strategy to tease apart any such cell-type specific 
functions for Shh would be transplantation studies. To that end, FACS could be used to 
separately isolate TncYFP-low, CD15+ and TncYFP-low, CD133+ populations from both WT TncYFP-CreER 
and TncYFP-CreER; SmoF/- mutant mice. Additionally, I would incorporate the Ai9 reporter strain to 
express an indelible tdTomato fluorophore to track recombined cells, which could then be 
transplanted into WT littermate recipients using stereotactic micro-injections.  
 
Having gained new insight into the distinct progenitor subpopulations occupying the neonatal 
cerebellar PWM raised intrigue regarding the medulloblastoma cell of origin. Currently, mouse 
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models indicate that medulloblastomas can arise from multi-potent cerebellar stem cells or 
granule cell committed precursors (Read et al., 2009; Sutter et al., 2010; Yang Z, 2008). A valid 
question to address now is whether TncYFP-low, CD15+ and/ or TncYFP-low, CD133+ cells could be 
transformed by oncogenic Shh pathway activation, leading to medulloblastoma. First, TncYFP-
CreER; SmoM2 mice could be administered TM and kept for observation. Such a strategy should 
indicate whether this outcome is possible or not. If so, the next step would be to dissect which 
progenitor, TncYFP-low, CD15+or TncYFP-low, CD133+ cells serve as tumor initiating cells. To this 
end, the above populations could be isolated from TncYFP-CreER; SmoM2 mice using FACS and 
transplanted into WT recipients.  
 
Another important future direction to consider is determining the mechanism by which PNs 
distribute Shh ligand over such a distance in two directions. The dissemination of Shh to the 
overlying EGL was first described in 1999 (Wechsler-Reya and Scott, 1999), but still we do not 
really understand how the molecule reaches such a distant target field two cortical layers away. It 
has been suggested that PN dendrites, which project towards the surface of the cerebellum, are 
the basis for Shh distribution (Lewis P.M., 2004). I found that PNs simultaneously transmit Shh 
inward to the PWM, and it appears that this likely occurs by utilizing PN axons that descend 
directly to the cerebellar core (Figure 3.12A-C’). It may be the case that these nascent neuronal 
projections aid in shuttling Shh bi-directionally, recent studies have shown that Shh-producing 
mesenchymal cells situated in the posterior compartment of the developing limb bud project 
dynamic filapodia to transmit Shh to receiving cells in the anterior compartment (Sanders et al., 
2013).  
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These specialized filapodial structures are highly dynamic and visualizing them requires live cell 
imaging, since traditional fixation methods apparently do not preserve them well. It is possible 
that PNs utilize a similar structure for transmitting Shh to the EGL. I have attempted to 
determine whether such a structure can be detected using a membrane-targeted YFP reporter 
(mT/mG) crossed to the ShhCre driver. Using fixed tissues, PNs from ShhCre; mT/mG cerebella 
appear to project long, thin structures into the overlying EGL, that are distinct from dendrites. 
Our lab has initiated studies utilizing live cell imaging on cerebellar slices from ShhCre; Ai9 mice 
and indeed, we have been able to visualize very long, thin PN projections that, to our knowledge, 
have not been reported anywhere in the literature. Our next step is to continue live cell imaging, 
but using ShhCre; mT/mG and/ or L7(Pcp2)-cre; mT/mG mice that should provide more stable and 
complete labeling of any membrane-bound cellular projections.  
 
Though these approaches should allow us to detect and study PN projections, they will not tell us 
about Shh ligand localization. To understand dynamics of Shh transmission, we can combine live 
cell imaging techniques with genetic studies and stereotactic micro-injections to deliver 
lentiviral-encoded, fluorophore tagged versions of Shh expressed under control of the L7(Pcp2) 
promoter. I have learned to perform these injections and have mapped coordinates to allow for 
reproducible injections into the neonatal cerebellum. These approaches should allow us to study 
distribution of PN-derived Shh in real time. It may be possible to simply culture live cerebellar 
slices in virus prior to imaging. However, once we have established a basic understanding of Shh 
transmission in the growing cerebellum, we can move toward genetic studies to uncover what 
molecules support this process.  
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Our lab has developed a conditional allele for Dispatched (Disp), a molecule thought to be 
required for Shh secretion and juxtacrine signaling (Kawakami et al., 2002). No doubt we could 
move our live imaging studies into a Disp mutant context; L7(Pcp2)-cre; DispF/- versus 
L7(Pcp2)-cre; DispF/+ littermates. To dissect mechanism(s) by which Shh could be targeted to 
and transmitted along the PN axon, conditional mutants for relevant microtubule-based motor 
proteins could be utilized. Kinesin-II, for instance, plays important roles in transporting cargoes 
along axons, and a floxed allele for the motor subunit, Kif3a, is readily accessible. Without a 
doubt, there are many avenues of inquiry left to follow up on the work in CHAPTER III;
the difficult task may be prioritizing where to look first. 
 
The studies in CHAPTER IV describing mouse sarcoma models and  possible function for Gli2 
in the etiology of EFT no doubt also highlight several future studies. The evidence indicating that 
GLI2 is likely an important mediator of EFT sarcomagenesis so far is limited; we know that 
GLI2 expression occurs at a high level in a substantial cohort of human EFT samples (n=154), 
and that ChIP-seq indicates that the EWS-FLI1 oncoprotein binds two regions on human Gli2, 
where it may act to induce GLI2 expression (Figure 4.7A-D). These data are strongly suggestive 
of a role for Gli2 in EFT, and furthermore our mouse modeling indicates that activation of Gli2 
alone is sufficient to drive EFT formation. However, several key issues remain unresolved in 
order to firmly document an EWS-FLI1 - Gli2 interaction, and to test whether Gli2 is indeed 
required in these tumors. In the long run, the application of our mouse model for screening 
potential therapeutic compounds should be considered. 
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So far we have mapped 21 potential EWS-FLI1 binding motifs distributed between two regions 
(1.8 kb and 1.7 kb) on human Gli2 that display the H3K27ac mark indicative of an active 
enhancer (Creyghton et al., 2010). The obvious next step is to perform ChIP experiments to 
clearly demonstrate that EWS-FLI1 does in fact bind GLI2. If binding can be demonstrated, then 
a next step would be testing whether EWS-FLI1 is sufficient to activate GLI2 expression via 
binding to these two regions. The latter can be cloned into the pGL3-promoter luciferase reporter 
construct, which would then be transfected into TC32, TC71, and A673 human EFT cells lines 
known to carry the EWS-FLI1 chimera for a cell-based reporter assay to measure GLI2 
activation. We can then knockdown EWS-FLI1 in TC32, TC71, and A673 EFT cells lines and 
measure whether this affects GLI2 expression and subsequent protein levels. EWS-FLI1 
knockdown can also be used as a control for ChIP experiments to assess whether binding to 
GLI2 is indeed EWS-FLI1 - mediated. 
 
Though these experiments will clearly indicate if EWS-FLI1 can directly activate GLI2, such 
data would not indicate if GLI2 activation is actually required for EFT formation. To address this 
question I would utilize a stable GLI2 knockdown in EFT cell lines that would then be used in 
xenograft studies with an established gastrocnemius transplantation model. Based on my data so 
far, I would anticipate a robust decrease in tumor forming potential with attenuated GLI2 
function. Altogether, these data would demonstrate that GLI2 is both necessary and sufficient for 
EFT formation. 
 
Because EFT data are not available through TCGA (the cancer genome atlas) yet, and extensive 
comparison of currently available microarray datasets with our RNA-seq results is problematic, I 
	   113	  
plan to perform comparisons of expression profiles from PCG2 tumors and EFT cell lines, TC32, 
TC71, and A673 once the latter become available through our collaborator, Patrick Grohar, MD, 
PhD. Such analyses will permit a more complete genome-wide comparison between our mouse 
model and human EFT, perhaps providing important further confirmation regarding the 
placement of our mouse model in the Ewing’s family. It may also help us gain insight into the 
differential regulation of target genes between GLI2 alone and EWS-FLI1. Such data could 
prove very helpful in understanding differences between the two entities, such as tumor 
aggressiveness, drug sensitivity, and site of tumor origin. In addition to soft tissue, EFT is also 
known to occur in the bone, something we have not seen in our mouse model. Expression data 
could be one approach to reconcile this difference. Fate-mapping studies of the L7(Pcp2)-cre 
lineage did indicate some contribution to bone, so it may seem somewhat strange that tumors 
never target bone in this model. EWS-FLI1 transcriptional regulation may impart different 
properties to tumors than GLI2 alone, allowing for differences such as this one. 
 
It is not really clear why so many past attempts to generate an EFT mouse model based on the 
EWS-FLI oncoprotein were not successful (Lin et al., 2008; Torchia et al., 2007), but one likely 
reason is the inherent lethality of oncoproteins (Haldar et al., 2007; Haldar et al., 2009; Straessler 
et al., 2013). Another possibility is that investigators have not identified the appropriate cellular 
lineage to target. Therefore, it would be worthwhile to create our own Rosa26-EWS-FLI1 mouse 
to cross with the L7(Pcp2)-cre driver used in our study. No one, so far, has targeted the EFT 
oncoprotein to this lineage, and it may be key to creating a bona fide EFT mouse using the most 
defining feature of Ewing’s, EWS-FLI1. Having this reagent would also allow us to further 
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elucidate the EFT cell of origin, since we could cross it with all the driver lines described in 
CHAPTER IV; Pax7-creER, Myf5Cre, aP2-cre and other available lines that we have not yet tried. 
 
A major conceptual realization to which my sarcoma studies have led, is that the level of Shh 
pathway activation dictates the resulting sarcoma phenotype; others have shown that activation at 
the level of Patched1/ Smo leads to RMS and now my work indicates that activation at the level 
of Gli2 induces EFT. To support this idea, it is important to differentially activate the pathway in 
the same lineage, to rule out the possibility that cellular origin contributes to tumor phenotype. A 
previously documented mouse model for RMS is the aP2-cre; SmoM2 mouse (Hatley et al., 
2012), which targets the adipocyte lineage similar to the aP2-cre; CLEG2 mice I described in 
CHAPTER IV. Even though we already know the outcome of generating aP2-cre; SmoM2 mice, 
having them would allow us to perform genome-wide RNA expression profiling between the two 
tumor types. Identifying the most highly, differentially expressed genes might lead us to find 
useful biomarkers to help further distinguish these two sarcoma variants. Additionally, we may 
be able to better understand what other factors shape the specific sarcoma phenotypic outcome, 
and even uncover potential therapeutic targets. 
 
Perhaps the most significant application for a mouse tumor model is in drug screening to test 
potential therapeutic compounds. While cells lines are more conducive to large-scale drug 
screens, mouse models can offer a powerful system to further evaluate promising compounds, 
understand their respective toxicities, etc. If the PCG2 model is truly an accurate recapitulation 
of EFT, then it should prove useful in testing compounds uncovered in screens utilizing human 
EFT cell lines. For instance, our collaborator Patrick Grohar has developed a compound that 
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blocks the DNA-binding of EWS-FLI1 to target genes (Grohar et al., 2011). Another 
collaborator at VUMC, Charles Hong, MD, PhD has developed a currently unpublished 
compound, Egmanone, which appears to inhibit the Shh pathway by disrupting Gli2 activity. Our 
lab has extensive unpublished data on a known compound called AICAR, which we have found 
potently blocks Gli2 function. Clearly, there is much further work that can be done with PCG2 
mice in the short term, without having to identify new compounds. To track tumor progression/ 
regression in real time, we have obtained a Gli1-luciferase reporter mouse that can provide an 
accurate read-out for pathway activity using bioluminescent, live animal imaging. 
 
Currently, there is a major need in the field for inhibitors of the Shh pathway that act 
downstream of Smo, where the action of most established inhibitors is targeted. The clinical 
application of Smo inhibitors has not been met with great success. For example, treatment of 
medulloblastoma using a Smo inhibitor from Genentech, GDC-0449, initially reduced one 
terminal patient’s tumor burden to an undetectable level. However, his cancer acquired a 
secondary mutation that blocked GDC-0449 activity, allowing a much more aggressive cancer to 
emerge (Yauch et al., 2009). Ideally, a combined approach to block pathway activity at multiple 
levels will be the future of targeted therapy. The generation of PCG2 mice came at what seems 
to be good timing, and the potential contribution that could be made with PCG2 mice to 
developing such approaches hopefully will be substantial. 
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